BIOGRAPHICAL Name: Edward Chu, MD Birth Date: Home … · BIOGRAPHICAL . Name: Edward Chu, MD Birth Date: December 19, 1958 Home Address: 121½ Springhouse Lane Birth Place: Detroit,

BIOGRAPHICAL Name: Edward Chu, MD Birth Date: December 19, 1958 Home Address: 121½ Springhouse Lane Birth Place: Detroit, Michigan Fox Chapel, PA 15238 Home Phone: (412) 406-7666 Citizenship: US Business Address: UPMC Cancer Pavilion, Fifth Floor, Room 571 5150 Centre Avenue Pittsburgh, PA 15232 E-Mail Address: [email protected] Business Phone: (412) 648-6589 Business Fax: (412) 648-6579

EDUCATION and TRAINING

UNDERGRADUATE: 1976-1980 Brown University B.S. – (Magna Cum Laude) Providence, RI Honors Thesis in Biology GRADUATE:

1983 Brown University M.M.S. (Pharmacology) Providence, RI 1983 Brown University School of Medicine MD

Providence, RI 1998 Yale University MA (hon) New Haven, CT POSTGRADUATE:

Dates Attended Name and Location of Institution Internship and Residency 1983-1987 Roger Williams General Hospital, Brown University, Providence, RI 1983-1984 Internship, Department of Medicine, Roger Williams General Hospital, Brown University, Providence, RI 1984-1985 Junior Resident, Department of Medicine, Roger Williams General

Hospital, Brown University, Providence, RI 1985-1986 Senior Resident, Department of Medicine, Roger Williams Hospital, Brown University, Providence, RI 1986-1987 Chief Medical Resident, Department of Medicine, Roger Williams General

Hospital, Brown University, Providence, RI

Medical Oncology Fellowship 1987-1990 National Cancer Institute, NIH, Bethesda, MD

ACADEMIC APPOINTMENTS and POSITIONS 1990-1992 Senior Staff Fellow, Medicine Branch, National Cancer Institute, NIH,

Bethesda, MD 1992-1996 Senior Clinical Investigator (tenured), NCI-Navy, Medical Oncology Branch,

National Cancer Institute, NIH, Bethesda, MD 1996-2001 Associate Professor of Medicine (tenured) and Pharmacology (secondary

appointment), Department of Medicine, Section of Medical Oncology, and Department of Pharmacology, Yale University School of Medicine, New Haven, CT

1996-2006 Chief of Hematology-Medical Oncology and Director, VACT Cancer Center, West Haven, CT

1996-2006 Associate Director for VA Oncology Program, Yale Cancer Center, New Haven, CT

2001-2010 Professor of Medicine (tenured) and Pharmacology (secondary appointment), Yale University School of Medicine, New Haven, CT

2004-2010 Chief, Section of Medical Oncology, Associate Director of Clinical/Translational Research, Yale Cancer Center, New Haven CT

2007-2010 Deputy Director, Yale Cancer Center, New Haven, CT 9/1/10-present Professor of Medicine and Pharmacology & Chemical Biology Chief, Division of Hematology-Oncology Associate Director, Drug Discovery Institute Deputy Director, University of Pittsburgh Cancer Institute University of Pittsburgh School of Medicine, Pittsburgh, PA 12/1/16-6/30/17 Interim Cancer Center Director, University of Pittsburgh Cancer Institute 10/1/17-present Stanley M. Marks-OHA Endowed Chair in Hematology-Oncology Research

and Leadership

MILITARY SERVICE 1989-1996 U.S. Public Health Service Active Duty

CERTIFICATION and LICENSURE SPECIALTY CERTIFICATION: Board certified in Internal Medicine, 1986 (Candidate No. 110810) Board certified in Medical Oncology, 1989 (Candidate No. 110810) MEDICAL LICENSURE: Licensing Board/State: Connecticut Medical License: No. 035221 Year: 1996-present

Licensing Board/State: Pennsylvania Medical License: MD440845 Year: 2010-present

MEMBERSHIPS in PROFESSIONAL and SCIENTIFIC SOCIETIES Organization: Year American Association for Cancer Research 1985 American Association for the Advancement of Science (Fellow) 2005 American College of Physicians (Fellow) 1985 American Federation for Medical Research 1985 American Society of Clinical Oncology 1990 European Society for Medical Oncology 2000 International Colorectal Cancer Club 1995

HONORS 1983 Sigma Xi 1992 NCI Commendation Medal 1996 PHS Achievement Medal 2005 Fellow, American Association for the Advancement of Science (AAAS) 2005-2012 New York Magazine Top Doctor (Medical Oncology) 2005-present Castle Connolly America’s Top Doctor for Cancer 2011-present U.S. News and World Report Top Doctor 2013 Chao Foundation Asian Leadership Award 2014 UPCI Merrill J. Egorin Excellence in Scientific Leadership Award 2014 Scott Wadler Memorial Lectureship, Visiting Professor, Weill Cornell Cancer Center 2014 Visiting Distinguished Professor, Peking University Cancer Hospital 2016 Fellow, American College of Physicians 2016 Charles M. Koller MD Lectureship Award, MD Anderson Cancer Center 2016 Pittsburgh Magazine Top Doctor (Medical Oncology) 2016 Ron Yount UPMC Compassionate Care Award 2016 2016 Chinese American Hematology-Oncology Network (CAHON) Lifetime Achievement Award 2017 Doctor Honoris Causa (Honorary Doctoral Degree) Athens National University and University of Athens Medical School 2019 Univ of Florida Health Cancer Center Visiting Professor 2019-present Distinguished Professor Xiangya Hospital, Central South University, Changsha, China

PUBLICATIONS 1. Refereed original articles

1. Chu SH, Ho L, Chu E, Savarese T, Chen ZH, Rowe EC, Chu MY. 5'-Halogenated formycins as inhibitors of 5-deoxy-5'-methylthioadenosine phosphorylase: protection of cells against the growth-inhibitory activity of 5'-halogenated adenosines. Nucleosides and Nucleotides. 1986;5:185-200.

2. Chu SH, Chen ZH, Weng ZY, Rowe EC, Chu E, Chu MY. Synthesis of variants of

5-benzylacyclouridine and 5-benzyloxybenzylacyclouridine. J. Heterocyclic Chem. 1986;23:1651. 3. Chu SH, Chen ZH, Weng ZY, Rowe E, Chu E, Wang Chu MY. Synthesis of aminomethyl and

amino analogs of 5-benzylacyclouridine and 5-benzyloxybenzylocyclouridine. J Heterocyclic Chem. 1987;24:989-995.

4. Chu SH, Weng ZY, Chen ZH, Rowe E, Chu E, Naguib FM, Kouni MH, Cha S, Chu MY. Synthesis

of 5-benzyl and 5-benzyloxybenzyl 2,2'-anhydrouridines and related nucleoside analogs as inhibitors of uridine phosphorylase. Nucleosides and Nucleotides. 1988;7:91-102.

5. Allegra CJ, Grem JL, Chu E, Johnston P, Yeh GC, Chabner BA. Antimetabolites. Cancer

Chemotherapy and Biological Response Modifiers. 1990;11:1-28. PMID: 2223392 6. Chu E, Drake JC, Boarman D, Baram J, Allegra CJ. Mechanism of thymidylate synthase inhibition

by methotrexate in human neoplastic cell lines and normal human myeloid progenitor cells. J Biol Chem. 1990;265:8470-8. PMID: 2341391

7. Chu E, Lai G-M, Zinn S, Allegra CJ. Resistance of a human ovarian cancer line to 5-fluorouracil

associated with decreased levels of 5-fluorouracil in DNA. Mol Pharmacol. 1990;38:410-7. PMID: 2402230

8. Chu E, Zinn S, Boarman D, Allegra CJ. Interaction of gamma-interferon and 5-fluorouracil in the

H630 human colon carcinoma cell line. Cancer Res. 1990;50:5834-40. PMID: 1697502 9. Chu E, Drake JC, Koeller DM, Zinn S, Jamis-Dow CA, Yeh GC, Allegra CJ. Induction of

thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol. 1991;39:136-43. PMID: 170499

10. Chu E, Koeller DM, Casey JL, Drake JC, Chabner BA, Elwood PC, Zinn S, Allegra CJ.

Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci USA. 1991;88:8977-81. PMID: 1924359. PMCID: PMC52634

11. Grem JL, Chabner BA, Chu E, Johnston P, Yeh GC, Allegra CJ. Antimetabolites. Cancer

Chemotherapy and Biological Response Modifiers. 1991;12:1-25. PMID: 1834143 12. Chu E, Chu MY, Darnowski JW, Chen ZH, Pan BC, Chu SH. Enhancement of

5-fluoro-2'-deoxyuridine antineoplastic activity by 5-benzyloxybenzylacyclouridine in a human colon carcinoma cell line. Cancer Res. 1992;52:1729-36. PMID: 1532344

13. Chu E, Grem JL, Johnston PG, Politi PM, Chabner BA, Allegra CJ. Antimetabolites. Cancer

Chemotherapy and Biological Response Modifiers. 1992;13:1-30. PMID: 1389906

14. Grem JL, Chu E, Boarman D, Balis FM, Murphy RF, McAtee N, Allegra CJ. Biochemical modulation of 5-fluorouracil with leucovorin and interferon: preclinical and clinical investigations. Semin Oncol. 1992;19:36-44. PMID: 1557656

15. Chu E, Allegra CJ. Regulation of thymidylate synthase in human colon cancer cells treated

with 5-fluorouracil and interferon-gamma. Adv Exp Med Biol. 1993;339:143-51. PMID: 8178713

16. Chu E, Johnston PG, Takimoto CH, Politi PM, Grem JL, Chabner BA, Allegra CJ.

Antimetabolites. Cancer Chemotherapy and Biological Response Modifiers. 1993;14:1-25. PMID: 8312100

17. Chu E, Koeller DM, Johnston PG, Zinn S, Allegra CJ. Regulation of thymidylate synthase in

human colon cancer cells treated with 5-fluorouracil and interferon-gamma. Mol Pharmacol. 1993;43:527-33. PMID: 8474431

18. Chu E, Takimoto CH, Voeller D, Grem JL, Allegra CJ. Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro. Biochemistry. 1993;32:4756-60. PMID: 8490020

19. Chu E, Voeller D, Koeller DM, Drake JC, Takimoto CH, Maley GF, Maley F, Allegra CJ.

Identification of an RNA-binding site for human thymidylate synthase protein. Proc Natl Acad Sci USA. 1993;90:517-21. PMID: 8421684

20. Takimoto CH, Voeller DB, Strong JM, Anderson L, Chu E, Allegra CJ. Effects of 5-fluorouracil

substitution on the RNA conformation and in vitro translation of thymidylate synthase messenger RNA. J Biol Chem. 1993 Oct 5;268(28):21438-42. PMID: 8407987

21. Chu E, Johnston PG, Grem JL, Takimoto CH, Van Groeningen C, Chabner BA, Allegra CJ.


22. Chu E, Voeller DM, Jones KL, Takechi T, Maley GF, Maley F, Segal S, Allegra CJ.

Identification of a thymidylate synthase ribonucleoprotein complex in human colon cancer cells. Mol Cell Biol. 1994;14:207-13. PMID: 8264588. PMCID: PMC358371

23. Chu E, Voeller DM, Morrison PF, Jones KL, Takechi T, Maley GF, Maley F, Allegra CJ. The

effect of reducing reagents on binding of thymidylate synthase protein to thymidylate synthase messenger RNA. J Biol Chem. 1994;269:20289-93. PMID: 8051122

24. Voeller D, Kovacs J, Andrawis V, Chu E, Masur H, Allegra C. Interaction of Pneumocystis

carinii dihydropteroate synthase with sulfonamides and diaminodiphenyl sulfone (Dapsone). J Infect Dis. 1994;169:456-9. PMID: 8106784

25. Chu E, Takechi T, Jones KL, Voeller DM, Copur SM, Maley GF, Maley F, Segal S, Allegra CJ.

Thymidylate synthase protein binds to c-myc RNA in human colon cancer cells and in vitro. Mol Cell Biol. 1995;15:179-85. PMID: 7799924. PMCID: PMC231930

26. Copur S, Aiba K, Drake JC, Allegra CJ, Chu E. Thymidylate synthase gene amplification in

human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol. 1995;49:1419-26. PMID: 7763285

27. Copur S, Dahut W, Chu E, Allegra CJ. Bone marrow aplasia and severe skin rash after a single low dose of methotrexate. Anti-Cancer Drugs. 1995;6:154-7. PMID: 7538828

28. Voeller DM, Changchien LM, Maley GF, Maley F, Takechi T, Turner RE, Montfort WR,

Allegra CJ, Chu E. Characterization of a specific interaction between Escherichia coli thymidylate synthase and Escherichia coli thymidylate synthase mRNA. Nucleic Acids Res. 1995;23:869-75. PMID: 7708505 PMCID: PMC306772

29. Chu E, Allegra CJ. Mechanisms of clinical resistance to 5-FU chemotherapy. Cancer

Treatment and Research. 1996;175-195. PMID: 8886453 30. Chu E, Allegra CJ. The role of thymidylate synthase as an RNA binding protein. BioEssays.

1996;18:191-8. PMID: 8867733

31. Chu E, Allegra CJ. The role of thymidylate synthase in cellular metabolism. Advances in Enzyme Regulation. 1996;36:143-63. PMID: 8869745

32. Chu E, Cogliati T, Borre A, Copur SM, Voeller DM, Allegra CJ, Segal S. Identification of in

vivo target RNA sequences bound by thymidylate synthase. Nucleic Acids Res. 1996;24:3222-8. PMID: 8774904. PMCID: PMC146086

33. Chu E, Grem JL, Johnston PG, Allegra CJ. New concepts for the development and use of

antifolates. Stem Cells. 1996;14:41-6. PMID: 8820950 34. Dearing MP, Englee-Miller MJ, Kratzke RA, Kramer BS, Chu E, Weinstein J, Anderson M,

Venzon D, Mulshine JL, Gazdar AF. Dipyridamole-mediated enhanced antiproliferative activity of 10-ethyl-10-deazaaminopterin (10-EDAM) against human lung cancer cell line. J Cell Biochem Suppl. 1996;24:165-72. PMID: 8806099

35. Johnston PG, Chu E, Allegra CJ. Antimetabolites. Cancer Chemotherapy and Biological

Response Modifiers. 1995;16:1-27. PMID: 8639379 36. Takimoto CH, Lu ZH, Zhang R, Liang MD, Larson LV, Cantilena LR, Jr, Grem JL, Allegra CJ,

Diasio RB, Chu E. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clinical Cancer Res. 1996;2:477-81. PMID: 9816193

37. Brandt DS, Chu E. Future challenges in the clinical development of thymidylate synthase

inhibitor compounds. Oncol Res. 1997;9(8):403-10. PMID:9436193 38. Johnston PG, Takimoto CH, Grem JL, Chabner BA, Allegra CJ, Chu E. Antimetabolites.

Cancer Chemotherapy and Biological Response Modifiers. 1997;17:1-39. PMID: 9551206 39. Pederson-Lane J, Maley GF, Chu E, Maley F. High level expression of human thymidylate

synthase. Protein Expression and Purification. 1997;10:256-62. PMID: 9226722 40. Chen Y, Sokoloski JA, Chu E, Sartorelli AC. Regulation of the expression of enzymes

involved in the replication of DNA in chemically-induced monocytic/macrophage differentiation of HL-60 leukemia cells. Leukemia Res. 1998;22:697-703. PMID: 9680096

41. Chen Y, Sokoloski JA, Chu E, Sartorelli AC. Regulation of the expression of enzymes

involved in the replication of DNA in chemically-induced granulocytic differentiation of HL-60

leukemic cells. Leuk Res. 1998 Aug;22(8):687-95. PMID: 9680095 42. Chu MY, Lipsky MH, Yee LK, Epstein J, Whartenby KA, Freeman S, Chen TM, Chu E,

Forman EN, Calabresi P. Predictive sensitivity of human cancer cells in vivo using semipermeable polysulfone fibers. Pharmacology. 1998;56:318-26. PMID: 9654219

43. Ju JF, Kane SE, Lenz HJ, Chu E, Danenberg KD, Danenberg PV. Desensitization and

sensitization of tumors to fluoropyrimidine with antisense against thymidylate synthase. Clin Cancer Res. 1998;4:2229-36. PMID: 9748143

44. Liu M, Pelling JC, Ju J, Chu E, Brash D. Antioxidant action via p53-mediated apoptosis.

Cancer Res. 1998; 58:1723-9. PMID: 9563490

45. Parsels LA, Chu E. The role for translational control of the cell cycle. Cancer J Sci Am. 1998;4:287-95. PMID: 9815290

46. Pizzorno G, Yee L, Burtness BA, Marsh JC, Darnowski JW, Chu MY, Chu SH, Chu E, Leffert

JJ, Handschumacher RE, Calabresi P. Phase I clinical and pharmacological studies of benzylacyclouridine (BAU), a uridine phosphorylase inhibitor. Clin Cancer Res. 1998;4:1165-75. PMID: 9607574

47. Schmitz JC, Agrawal S, Chu E. Repression of human thymidylate synthase mRNA translation

by antisense 2’-O-methyl oligoribonucleotides. Antisense Nucleic Acids Dev. 1998;8:371-8. PMID: 9826264

48. Yee L, Chu E, Pan BC, Chu SH, Chen TM, Lipsky MH, Chu MY, Calabresi P.

Benzylacyclouridine (BAU) enhances 5-fluorouracil cytotoxicity against human prostate cancer cell lines. Pharmacology. 1998;56:80-91. PMID: 9494066

49. Pan BC, Chen ZH, Chu E, Chu MY, Chu SH. Synthesis of

5-halogeno-6-amino-2’-deoxyuridines and their analogs as potential inhibitors of thymidine phosphorylase. Nucleosides and Nucleotides. 1998;17(12):2367-2382.

50. Chu E, Copur SM, Ju J, Chen TM, Khleif S, Voeller DM, Mizunuma N, Patel M, Maley GF,

Maley F, Allegra CJ. Thymidylate synthase and p53 mRNA form an in vivo ribonucleoprotein complex. Mol Cell Biol. 1999;19:1582-94. PMID: 9891091 PMCID: PMC116086

51. Grem JL, Takimoto CH, Multani P, Chu E, Ryan D, Chabner BA, Allegra CJ, Johnston PG.


52. Ju J, Pedersen-Lane J, Maley F, Chu E. Regulation of p53 expression by thymidylate

synthase. Proc. Natl. Acad. Sci. USA. 1999;96:3679-3774. PMID: 10097112 PMCID: PMC22369

53. Lin X, Mizunuma N, Chen T, Copur SM, Maley GF, Liu J, Maley F, Chu E. In vitro selection of

an RNA sequence that interacts with high affinity with thymidylate synthase. Nucleic Acids Res. 2000 Nov 1;28(21):4266-74. PMID: 11058126 PMCID: PMC113123

54. Lin X, Parsels LA, Voeller DM, Allegra CJ, Maley GF, Maley F, Chu E. Characterization of a

cis-acting regulatory element in the protein-coding region of thymidylate synthase mRNA. Nucleic Acids Res. 2000;28:1381-9. PMID: 10684933 PMCID: PMC111044

55. Liu J, Nau MM, Yeh JC, Allegra CJ, Chu E, Wright JJ. Molecular heterogeneity and function

of EWS-WT1 fusion transcripts in desmoplastic small round cell tumors. Clin Cancer Res. 2000;6:3522-9. PMID: 10999739

56. Copur MS, Ledakis P, Bolton M, Morse AK, Werner T, Norvell M, Muhvic J, Chu E. An

adverse interaction between warfarin and capecitabine: a case report and review of the literature. Clin Colorectal Cancer. 2001;1:182-4. PMID: 12450435

57. Liu J, Grogan L, Nau MM, Allegra CJ, Chu E, Wright JJ. Physical interaction between p53

and primary response gene Egr-3, Int J Oncol. 2001;18:863-70. PMID: 11251186 58. Schmitz JC, Liu J, Lin X, Chen T, Yan W, Tai N, Gollerkeri A, Chu E. Translational regulation

as a novel mechanism for the development of cellular drug resistance. Cancer Metast Rev. 2001;20:33-41. PMID: 11831645

59. Schmitz JC, Yu D, Agrawal S, Chu E. Effect of 2’-O-methyl antisense ORNs on expression of

thymidylate synthase in human colon cancer RKO cells. Nucleic Acids Res. 2001;29:415-22. PMID: 11139611. PMCID: PMC29681

60. Johnson L, Chu E. Lack of benefit of 5-fluorouracil-based adjuvant chemotherapy in

colorectal cancer with microsatellite instability. Clin Colorectal Cancer. 2002;2:146-8. PMID: 12482330

61. Liu J, Schmitz JC, Lin X, Tai N, Yan W, Farrell MP, Bailly M, Chen TM, Chu E. Thymidylate

synthase as a translational regulator of cellular gene expression. Biochim Biophys Acta. 2002;1587:174-82. PMID: 12084459

62. Tai N, Ding Y, Schmitz JC, Chu E. Identification of critical amino acid residues on human

dihydrofolate reductase protein that mediate RNA recognition. Nucleic Acids Res. 2002 Oct 15;30(20):4481-8. PMID: 12384595. PMCID: PMC137126

63. Chu E, Callender MA, Farrell MP, Schmitz JC. Thymidylate synthase inhibitors as anticancer

agents: from bench to bedside. Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S80-9. Epub 2003 Jun 18. PMID: 12819937

64. Chu E. The role of sequential therapy in the treatment of advanced colorectal cancer.

Oncology. 2003;1-8. 65. Chu E. Efficacy and safety of capecitabine therapy for colorectal cancer. Amer J Oncol Rev.

2003;2(Suppl. 3):4-28. 66. Lin X, Liu J, Maley F, Chu E. Role of cysteine amino acid residues on the RNA binding

activity of human thymidylate synthase. Nucleic Acids Res. 2003 Aug 15;31(16):4882-7. PMID: 12907731. PMCID: PMC169953

67. DiPaolo A, Chu E. The role of thymidylate synthase as a molecular biomarker. Clin Cancer

Res. 2004;10(2):411-2. PMID: 14760058 68. Schmitz JC, Chen TM, Chu E. Small interfering double-stranded RNAs as therapeutic

molecules to restore chemosensitivity to thymidylate synthase inhibitor compounds. Cancer Res. 2004;64:1431-5. PMID: 14973067

69. Tai N, Schmitz JC, Chen TM, Chu E. Characterization of a cis-acting regulatory element in

the protein-coding region of dihydrofolate reductase mRNA. Biochem J. 2004 Mar 15;378(Pt 3):999-1006. PMID: 14664697. PMCID: PMC1224025

70. Tai N, Schmitz JC, Liu J, Lin X, Bailly M, Chen TM, Chu E. Translational autoregulation of

thymidylate synthase and dihydrofolate reductase. Front Biosci. 2004;9:2521-6. PMID: 15353304

71. Aggarwal S, Chu E. Current therapies for advanced colorectal cancer. Oncology (Williston

Park). 2005 Apr;19(5):589-95. PMID:15945340 72. Chu E. Commentary on advances in the management of advanced colorectal cancer, In: Chu,

E. (Ed), Important Advances in the Management of Advanced Colorectal Cancer, Oncology. 2005;19(Suppl 6):9-24.

73. Murren J, Modiano M, Kummar S, Clairmont C, Egorin M, Chu E, Sznol M. A phase I and

pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer. Invest New Drugs. 2005;23:123-35. PMID: 15744588

74. Chu E, Einhorn LE, Lefebvre P. Clinical benefits of once-weekly epoetin alfa in anemic

patients with colorectal cancer receiving chemotherapy. J Support Oncol. 2006;4:243-50. PMID: 16724648

75. Du C, Niu R, Chu E, Zhang P, Lin X. Sequence analysis and functional study of thymidylate

synthase from zebrafish, Danio rerio. J Biochem. 2006;139:913-20. PMID: 16751599 76. Mulkeen AL, Silva T, Yoo PS, Schmitz JC, Uchio E, Chu E, Cha C. Short interfering

RNA-mediated gene silencing of vascular endothelial growth factor: effects on cellular proliferation in colon cancer cells. Arch Surg. 2006;14:367-74. PMID: 16618894

77. Saif MW, Kang SP, Chu E. Treatment of metastatic colorectal cancer: from cytotoxic agents

to molecular agents and multitargeted strategies. Oncology (Williston Park). 2006 Dec;20(14 Suppl 10):11-9. PMID: 17354513

78. Vokes E, Chu E. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and

neck cancers. Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):15-25. PMID: 16736979 79. Xi Y, Nakajima G, Schmitz JC, Chu E, Ju J. Multilevel gene expression profiles affected by

thymidylate synthase and 5-fluorouracil in colon cancer. BMC Genomics. 2006;3:68-78. PMID: 16584549. PMCID: PMC1448211

80. Grothey E, Chu E. The clinical efficacy of FOLFIRI and bevacizumab in combination as

first-line therapy of metastatic colorectal cancer. Clin Colorectal Cancer. 2007;6:621-4. PMID: 17945033

81. Ju J, Schmitz JC, Song B, Kudo K, Chu E. Regulation of p53 expression in response to

5-fluorouracil in human cancer RKO cells. Clin Cancer Res. 2007;13:4245-51. PMID: 17634554

82. Lee JJ, Chu E. An update on treatment advances for the first-line therapy of metastatic

colorectal cancer. Cancer J. 2007;13:276-82. PMID: 17921724

83. Carducci MA, Chu E, Venook AP, Greco FA, Gregory SA. Highlights from the 40th annual

meeting of the American Society of Clinical Oncology. Clin Adv Hematol Oncol. 2006; 2:512-526.

84. Lee JJ, Chu E. First-line use of anti-epidermal growth factor receptor monoclonal antibodies

in metastatic colorectal cancer. Clin Colorectal Cancer. 2007 Oct;6 Suppl 2:S42-6. PMID:18021486

85. Lee JJ, Chu E. Update on clinical data combining capecitabine with targeted agents in newly

diagnosed colorectal cancer. Clin Colorectal Cancer. 2007;7(Suppl 1):S16-20. PMID: 18361802 86. Wang Z, Zheng L, Yang S, Niu R, Chu E, Lin X. N-acetylchitooligosaccharide is a potent

angiogenic inhibitor both in vivo and in vitro. Biochem Biophys Res Commun. 2007; 357:26-31. PMID: 17400187

87. Chu E, Cartwright TH. The pharmacoeconomic benefits of capecitabine-based chemotherapy

in metastatic colorectal cancer. J Clin Oncol. 2008;26:2224-6. PMID: 18445854

88. DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68:8643-53. PMID: 18974103

89. Lenz HJ, Chu E, Grothey A. KRAS mutation in metastatic colorectal cancer and its impact on

the use of EGFR inhibitors. Clin Adv Hematol Oncol. 2008 Dec;6(12):1-13, 14-6. PMID: 19378369

90. Tai N, Schmitz JC, Chen TM, O’Neill MB, Chu E. Identification of a cis-acting element of

human dihydrofolate reductase mRNA. Biochem Biophys Res Commun. 2008;369:795-800. PMID: 18045573

91. Chu E, Schulman KL, Zelt S, Song X. Costs associated with complications are lower with

capecitabine than with 5-fluorouracil in patients with colorectal cancer. Cancer. 2009;115:1412-23. PMID: 19195048

92. Chu E, Shi N, Wei W, Bendell JC, Cartwright T. Costs associated with capecitabine or

5-fluorouracil monotherapy after surgical resection among patients with colorectal cancer. Oncology. 2009;77(3-4):244-53. PMID: 19738390

93. Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically-guided dose adjustment of

5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst. 2009;101:1543-52. PMID: 19841331

94. Yen Y, So S, Rose M, Saif MW, Chu E, Liu SH, Foo A, Su T, Cheng YC. Phase I/II study of

PHY906 /capecitabine in advanced hepatocellular carcinoma. Anticancer Res. 2009;29:4083-92. PMID: 19846955

95. Chu E, Schulman K, McKenna E, Cartwright T. Patients with locally advanced and metastatic

colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison. Clin Colorectal Cancer. 2010;9:279-237. PMID: 20920995

96. Kudo K, Xi Y, Wang Y, Song B, Chu E, Ju J, Russo JJ, Ju J. Translational control analysis by

translationally active RNA capture/microarray analysis (TrIP-Chip). Nucleic Acids Res. 2010;38:e104. PMID: 20123731. PMCID: PMC2875024

97. Saif MW, Chu E. Biology of colorectal cancer. The Cancer Journal: Journal of Principles and

Practice of Oncology. 2010;16:196-201. PMID: 20526096 98. Saif MW, Kaley K, Chu E, Copur MS. Safety and efficacy of panitumumab therapy after

progression with cetuximab: experience at two institutions. Clin Colorectal Cancer. 2010;9:315-8. PMID: 21208847

99. Zhang W, Saif MW, Dutschman GE, Li X, Lam W, Bussom S, Jiang Z, Ye M, Chu E, Cheng

YC. Identification of chemicals and their metabolites from PHY906, a Chinese herbal medicine, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC-MS). J Chromatography A. 2010;1217:5785-5793. PMID: 20696432

100. Zhang Y, Yang S, Liu M, Song C, Wu N, Ling P, Chu E, Lin X. Interaction between

thymidylate synthase and its cognate mRNHA in zebrafish embryos. PLOS One. 2010;5:1-10. PMID: 20485548. PMCID: PMC2868900

101. El-Ghazal R, Podoltsev N, Marks P, Chu E, Saif MW. Mitomycin-c induced thrombotic

thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new ear. Clin Colorectal Cancer 2011;10:142-145. PMID: 21859568

102. Hopkins CD, Schmitz JC, Chu E, Wipf P. Total synthesis of (-)-CP(2)-disorazole C(1). Org

Lett. 2011;13:4088-4091. PMID: 21739942. PMCID: PMC3160746 103. Kummar S, Copur MS, Rose, M, Wadler S, Stephenson J, O’Rourke M, Breckman W, Tilton

R, Liu SH, Jiang Z, Su T, Cheng YC, Chu E. A phase I study of the Chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2011;10:85-96. PMID: 21859559

104. Schmitz, JC, Chu, E. Effect of small interfering RNA 3’-end overhangs on chemosensitivity to

thymidylate synthase inhibitors. Silence. 2011;2:1-6. PMID: 21247442. PMCID: PMC3035029

105. Zhang W, Tan S, Paintsil E, Dutschman GE, Gullen EA, Chu E, Cheng YC. Analysis of deoxyribonucleotide pools in human cancer cell lines using a liquid chromatography coupled with tandem mass spectrometry technique. Biochem Pharmacol. 2011;82:411-417. PMID: 21620803. PMCID: PMC3138996

106. Chu E. Application of microsatellite instability and Oncotype DX in stage II colon cancer

adjuvant chemotherapy. Curr Colorectal Cancer Rep. (2011) 7:260-266 doi: 10.1007/s11888-011-0105-2.

107. Bartlett DL, Chu E. Can metastatic colorectal cancer be cured? Oncology (Williston Park).

2012;26:266-75. PMID: 22545311 108. Beumer JH, Chu E, Salamone SJ. Body-surface area-based chemotherapy dosing:

appropriate in the 21st century? J Clin Oncol. 2012;30:3896-7. PMID: 22965963.

109. Cheng L, Wang C, Liu H, Wang F, Zheng L, Zhao J, Chu E, Lin X. A novel polypeptide extracted from Ciona savignyi induces apoptosis through a mitochondrial-mediated pathway

in human colorectal carcinoma cells. Clin Colorectal Cancer. 2012;11:207-14. doi: 10.1016/j.clcc.2012.01.002. Epub 2012 Mar 21. PMID: 22440403

110. Chu E. An update on the current and emerging trends in metastatic colorectal cancer. Clin

Colorectal Cancer. 2012;11:1-13. PMID: 21752724. 111. Li J, Lee JJ, Chu E, Baehring JM. Reversible leukoencephalopathy with stroke-like

presentation in a patient with 5-dihydropyrimidine dehydrogenase deficiency treated with continuous 5-fluorouracil infusion. Clin Colorectal Cancer. 2012;11:215-7. PMID: 22410472.

112. Wu SY, Chen TM, Gmeiner WH, Chu E, Schmitz JC. Development of modified siRNA

molecules incorporating 5-fluoro-2’-deoxyuridine residues to enhance cytotoxicity. Nucleic Acids Res. 2013;41:4650-4659. PMID: 23449220; PMCID: PMC3632118.

113. Kiesel BF, Parise RA, Tjornelund J, Christensen MK, Loza E, Tawbi H, Chu E, Kummar S,

Beumer JH. LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma. J Pharm Biomed Anal. 2013;81-82:89-98. PMID: 23644904; PMCID: PMC3663884.

114. Hartman DJ, Nikiforova MN, Chang DT, Chu E, Bahary N, Brand RE, Zureikat AH, Zeh HJ,

Choudry H, Pai RK. Signet ring cell colorectal carcinoma: a distinct subset of mucin-poor microsatellite-stable signet ring cell carcinoma associated with dismal prognosis. Am J Surg Pathol. 2013;37:969-977. PMID: 23681075.

115. Schenker Y, Crowley-Matoka M, Dohan D, Rabow MW, Smith CB, White DB, Chu E, Tiver

GA, Einhorn S, and Arnold RM. Oncologist factors that influence referrals to subspecialty palliative care clinics. J Oncology Practice. 2014;10:e37-44. PMID: 24301842 PMCID: PMC3948709

116. Maciasz R, Arnold RM, Chu E, Park SY, White D, Borgenheimer L, Schenker Y. Does it

matter what you call it? A randomized trial of language used to describe palliative care services. Support Care Cancer. 2013 Dec;21(12):3411-9. PMID: 23942596 PMCID: PMC3823760.

117. Lee JJ, Chu E. Oncotype Dx for colon cancer: are we ready for prime time in personalized

medicine? Curr Colorectal Cancer Rep. (2013) 9:312-316 doi: 10.1007/s11888-013-0186-1. 118. Lee JJ, Chu E. Personalized medicine in the adjuvant chemotherapy of stage II colon

cancer–are we there yet? Oncology (Williston Park). 2013 Aug;27(8):754, 756-8. PMID: 24133821.

119. Tawbi H, Christner SM, Lin Y, Johnson M, Mowrey ET, Cherrin C, Chu E, Lee JJ, Puhalla S,

Stoller R, Appleman LR, Miller BM, Beumer JH: Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers. Cancer Chemother Pharmacol. 73:207-11, 2014. PMID: 24170263; PMCID: PMC3880632.

120. Parikh RA, Wang P, Beumer JH, Chu E, Appleman LJ. The potential role of hepatocyte

growth factor (HGF)-MET pathway inhibitors in cancer treatment. Onco Targets Ther. 2014;7:969-983. PMID: 24959084; PMCID: PMC4061161.

121. Liu H, Schmitz JC, Wei J, Cao S, Beumer JH, Strychor S, Cheng L, Liu M, Wang C, Chu E,

Lin X. Clove extract inhibits tumor growth and promotes cell cycle arrest and apoptosis.

Oncology Res. 2014;21:247-259. PMID: 24854101 PMCID: PMC4132639 122. Chu E, Haller D, Cartwright T, Twelves C, Cassidy J, Sun W, Saif MW, McKenna E, Lee S,

Schmoll H-J, Epidemiology and natural history of central venous access devices and infusion pump function in the NO16966 trial. Br J Cancer. 2014;110:1438-45. PMID: 24548866 PMCID: PMC3960626

123. Lee JJ, Chu E. Sequencing of anti-angiogenic agents in the treatment of metastatic colorectal

cancer. Clin Colorectal Cancer 2014;13:135-144. PMID: 24768040 124. Wei N, Chu E, Wipf P, Schmitz JC. Protein kinase D as a potential chemotherapeutic target

for colorectal cancer. Mol Cancer Ther. 2014;13:1130-1141. PMID: 24634417 PMCID: PMC4019967

125. Vater LB, Donohue JM, Arnold R, White DB, Chu E, Schenker Y. What are cancer centers

advertising to the public?: a content analysis. Ann Intern Med. 2014;160:813-820. PMID: 24863081 PMCID: PMC4356527

126. Chu E. Tumor heterogeneity and implications for clinical practice. Oncology (Williston Park).

2014 Sep;28(9):726, 741. PMID: 25224470.

127. Wei N, Chu E, Wu SY, Wipf P, Schmitz JC. The cytotoxic effects of regorafenib in combination with protein kinase D in human colorectal cancer cells. Oncotarget. 2015;6:4745-4756. PMID: 25544765; PMCID: PMC4467112.

128. Schenker Y, White D, Rosenzweig M, Chu E, Moore C, Ellis P, Nikolajski P, Ford C, Tiver G,

McCarthy L, Arnold R. Care management by oncology nurses to address palliative care needs: a pilot trial to assess feasibility, acceptability, and perceived effectiveness of the CONNECT intervention. J Palliative Med. 2015;18:232-240. PMID: 25517219; PMCID: PMC4347888.

129. Lam W, Jiang Z, Guan F, Hu R, Liu SH, Chu E, Cheng YC. The number of intestinal bacteria

is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018). BMC Complement Altern Med. 2014;14:490. PMID: 25510341; PMCID: PMC4302098.

130. Soni A, Chu E. Cost-effectiveness of adjuvant chemotherapy in the treatment of early-stage

colon cancer. Clin Colorectal Cancer. 2015;14:219-226. PMID: 26072443 131. Appleman LJ, Balasubramaniam, S, Parise RA, Bryla C, Redon CE, Nakamura AJ, Booner

WM, Wright JJ, Piekarz R, Kohler DR, Jiang Y, Belani CP, Eiseman J, Chu E, Beumer JH, Bates SE. A phase I study of DMS612, a novel bifunctional alklyating agent. Clin Cancer Res. 2015;21:721-729. PMID: 25467180; PMCID: PMC4755291.

132. Wu S, Guo Z, Hopkins CD, Wei N, Wipf P, Chu E, Schmitz JC. Bis-cyclopropane analog of

disorazole C1 is a microtubule-destabilizing agent active in ABCB1-overexpressing human colon cancer cells. Oncotarget. 2015;6:40866-79. PMID: 26506423; PMCID: PMC4747374.

133. Lee JJ, Beumer JH, Chu E. Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother

Pharmacol. 2016;78:447-64. PMID: 27217046. 134. Lee JJ, Seraj J, Yoshida K, Mizuguchi H, Strychor S, Fiejdasz J, Faulkner T, Parise RA,

Fawcett P, Pollice L, Mason S, Hague J, Croft M, Nugteren J, Tedder C, Sun W, Chu E, Beumer JH. Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry. Cancer Chemother Pharmacol. 2016;77:515-26. PMID: 26787503; PMCID: PMC4767595.

135. Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Weiss GJ,

Sachdev JC, Chadha M, Fulk M, Ejadi S, Mountz, MJ, Lotze MT, Toledo FGS, Chu E, Jeffers M, Pena C, Xia C, Reif C, Genvresse I, Ramanathan RK. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor in patient with advanced solid tumors and non-Hodgkin’s lymphomas. Ann Oncol. 2016;27:1928-40. PMID: 27672108.

136. Parikh RA, Appleman LJ, Beumer JH, Matczak E, Chu E. Tyrosine kinase mTOR inhibitors in the treatment of advanced renal cell carcinoma: practical implications of pharmacologic features. Clin Genitourin Cancer. 2017;15:7-22. PMID: 27473523.

137. Kunos CA, Chu E, Beumer JH, Sznol M, Ivy SP. Phase I trial of daily triapine in combination

with cisplatin chemotherapy for advanced-stage malignancies. Cancer Chemother Pharmacol. 2017;79:201-207. PMID: 27878356.

138. Lee JJ, Chu E. Adherence, dosing, and managing toxicities with trifluridine/tipiracil (TAS-102).

Clin Colorectal Cancer. 2017;16:85-92. PMID: 28242161. 139. Kunos CA, Chu E, Makower D, Kaubisch A, Sznol M, and Ivy SP. Phase I trial of

triapine-cisplatin-paclitaxel chemotherapy for advanced stage of metastatic solid tumor cancers. Front Oncology. 2017;7:1-8. PMID: 28421163.

140. Niu J, Scheuerell C, Mehrotra S, Karan S, Puhalla S, Biesel BF, Ji J, Chu E, Gopalakrishnan

M, Ivaturi V, GobburuJ, Beumer JH. Parent-metabolite pharmacokinetic modeling and pharmacodynamics of veliparib (ABT-888), a PARP inhibitor, in patient with BRCA ½-mutated cancer of PARP-sensitive tumor types. J Clin Pharmacol 2017;57:977-987. PMID: 28387939.

141. Stoller R, Schmitz JC, Ding F… Chu E, and Beumer JH. Phase I study of veliparib in

combination with gemcitabine. Cancer Chemother Pharmcol 2017 Aug 2. Doi: 10.1007/s00280-017-3490-3. PMID: 28770300.

142. Matsumoto J, Kiesel B, Parise R, Guo J, Taylor S, Huang M, Eiseman J, Ivy P, Kunos C, Chu

E, and Beumer JH. LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma. J Pharm Biomed Anal 2017;146:154-160. PMID: 28881312.

143. Kiesel B, Scemama, Parise R, Villaruz L… Chu E, Bakkenist C, and Beumer JH. LC-MS/MS

assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma. J Pharm Biomed Anal 2017;146:244-250. PMID: 28888173.

144. Schenker Y, Bahary N, Claxton R, Childers J, Chu E, Kavalieratos D, King L, Lembersky B,

Tiver G, Arnold RM. A pilot trial of early specialty palliative care for patients with advanced pancreatic cancer: challenges encountered and lessons learned. J Palliat Med 2017 Aug 3. Doi: 10.1089/jpm.2017.0113. PMID: 28772092.

145. Atreya CA, Yaeger R, Chu E. Systemic therapy for metastatic colorectal cancer: from current

standards to future molecular targeted approaches. Am Soc Clin Oncol Educ Book.

2017;37:246-256. PMID: 28561718. 146. Xi D, Bao T, Chen Q…. Paller CJ, and Chu E. State of the science: cancer complementary

and alternative medicine therapeutics research – NCI Strategic Workshop highlights of discussion report. J Natl Cancer Inst Monogr. 2017;2017 (52). PMID: 29140484.

147. Liu H, Liu H, Zhou Z, Parise RA, Chu E, Schmitz JC. Herbal formula Huan Qin GeGen Tang

enhances 5-fluorouracil antitumor activity through modulation of the E2F1/TS pathway. Cell Commun Signal 2018;16:7. PMID: 29458395

148. Chu E. Wedding rigorous scientific methodology and ancient herbal wisdom to benefit cancer

patients: the development of PHY906. Oncology 2018;32:e20-e27. PMID: 29492950. 149. Chu E. How I treat chemorefractory metastatic colorectal cancer. Clin Adv Hematol Oncol

2018;16:340-345. PMID: 29851930. 150. Lee JJ and Chu E. Recent advances in the clinical development of immune checkpoint

blockade therapy for mismatch repair proficient (pMMR)/non-MSI-H metastatic colorectal cancer. Clin Colorectal Cancer 2018;17:258-273. PMID: 30072278.

151. Beumer JH, Chu E, Allegra CJ, Tanigawara Y, Milano G, Diasio R, Kim TW, Mathijssen RH,

Zhang L, Arnold D, Muneoka K, Boku N, Joerger M. Therapeutic drug monitoring in oncology: IATDMCT recommendations for 5-fluorouracil. Clin Pharmacol Ther 2018. doi: 10.1002/cpt. 1124. [Epub ahead of print]. PMID: 29923599.

152. Lee JJ and Chu E. The adjuvant treatment of stage III colon cancer: might less be more?

Oncology 2018;32:437-442. PMID: 30248163. 153. Sun W, Patel A, Normolle D, Patel K, Ohr J, Lee J, Bahary N, Chu E, Streeter N, and

Drummond S. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy refractory advanced and metastatic biliary tract adenocarcinoma. Cancer 2019;125:902-909. PMID: 30561756.

154. Wei N, Li J, Fang C,…, Chu E, Schmitz JC. Targeting colon cancer with the novel STAT3

inhibitor bruceantinol. Oncogene 2019;38:1676-1687. PMID: 30348989. 155. Ganguly A, Frank D, Kuma N, Cheng YC, and Chu E. Biomarkers for cancer complementary

and alternative medicine. Current Oncol Rep 2019. doi: 10.1007/s11912-019-0782-6. PMID: 30834992.

156. Quantitation of paclitaxel and its 6-alpha-OH and 3-para-OH metabolites in human plasma by

LC-MS/MS. Christner SM, Marise RA, Ivy PS, Tawbi H, Chu E, and Beumer JH. J Pharm Biomed Anal. 2019;172:26-32. PMID: 31022613.

2. Book Chapters 1. Allegra CJ, Chu E. Strategies for circumventing clinical resistance to 5-fluorouracil. In: Mihich E. (Ed),

Drug Resistance: Mechanisms and Reversal, 71-88, 1989. 2. Brandt DS, Chu E. The development of TS inhibitor compounds in the treatment of human colorectal

cancer. In: Colon Cancer - The Cutting Edge. Chu E. (Ed), Innovative Medical Communications, 1-4,

1999. 3. Chu E, Takimoto CH. Antimetabolites. In: DeVita VT, Hellman S and Rosenberg SA. (Eds), Cancer:

Principles and Practice of Oncology, Second Edition, J.B. Lippincott Co., Philadelphia, 1993, pp. 358-374.

4. Chu E Allegra CJ. Antifolates. In: Chabner BA and Collins JM. (Eds), Cancer Chemotherapy, 109-148,

1996. 5. Chu E, Allegra CJ. Mechanisms of clinical resistance to fluoropyrimidine chemotherapy. In: Lippman

ME and Dickson RB (Eds), Drug and Hormonal Resistance in Breast Cancer, Ellis Horwood, West Sussex, England, 1995, pp. 283-301.

6. Chu E, Schmitz JC, Ju J, Copur S. An immunoprecipitation-RNA:rPCR method for the in vivo isolation of

ribonucleoprotein complexes. In: Methods in Molecular Biology: RNA-Protein Interaction Protocols. Haynes S. (Ed), Humana Press, 118, 265-274, 1999.

7. Chu E, Schmitz JC, Ju J. Molecular regulation of expression of thymidylate synthase. In: Cancer Drug

Discovery and Development: Antifolate Drugs - Basic Research and Clinical Practice. Jackman AL. (Ed), Humana Press, 397-408, 1999.

8. Brandt D, Canova A, Chu E. Rescue of host toxicity from 5-FU and antifolate TS inhibitor compounds. In:

Colon Cancer - The Cutting Edge. Chu E. (Ed), IMC Publishing, 1998. 9. Mota AC, Fogarasi MC, Chu E. Review of the clinical activity of eniluracil in combination with

5-fluorouracil. In: Cancer Conference Highlights. Jain V. (Ed), IMC Publishing, 1999. 10. Chu E, Mota A, Fogarasi M. Antimetabolites. In: DeVita VT, Hellman S, and Rosenberg SA. (Eds),

Cancer: Principles and Practice of Oncology, Six Edition, J.B. Lippincott Co., Philadelphia, 388-415, 2000.

11. Chu E, DeVita VT. Principals of Chemotherapy. In: DeVita VT, Hellman S, and Rosenberg SA. (Eds),

Cancer: Principles and Practice of Oncology, Six Edition, J.B. Lippincott Co., Philadelphia, 289-306, 2000.

12. Chu E, Chabner BA. Drug Development. In: DeVita VT, Hellman S, and Rosenberg SA. (Eds), Cancer:

Principles and Practice of Oncology, Six Edition, J.B Lippincott Co., Philadelphia, 345-356, 2000. 13. Gollerkeri A, Chu E. Resistance to inhibitor compounds of thymidylate synthase. In: Bertino JR. (Ed),

Encylcopedia of Cancer, Second Edition, Academic Press, San Diego, 2000. 14. Schmitz JC, Gollerkeri A, Liu J, Lin X, Chu E. Molecular mechanisms of regulation of thymidylate

synthase. In: Cancer Drug Discovery and Development: Fluoropyrimidines in Cancer Therapy. Rustum YM. (Ed), Humana Press, 67-82, 2001.

15. Schmitz JC, Chu E. Translational regulation of thymidylate synthase and the cell cycle: insights for

clinical drug development. In: Progress in Oncology 2003. DeVita VT, Hellman S, and Rosenberg SA. (Eds), Jones and Bartlett, Boston, p. 23-45, 2004.

16. Chu E, Sartorelli AC. Cancer Chemotherapy. In: Basic and Clinical Pharmacology, 9th Edition. Katzung

BG. (Ed), McGraw-Hill, New York, N.Y., 2003.

17. Chu E. Oxaliplatin: the new member of the class (preclinical, phase I/II), In: Marshall J. (Ed), The Clinical Use of Oxaliplatin, CMP Healthcare Media, Manhasset, NY, 1-10, 2004.

18. Kummar S, Noronha V, Chu E. Antimetabolites. In: DeVita VT, Hellman S, and Rosenberg SA. (Eds),

Cancer: Principles and Practice of Oncology, Seventh Edition, JB Lippincott Co, Philadelphia, 2005. 19. Chu E, DeVita VT. Principals of Chemotherapy. In: Cancer: Principles and Practice of Oncology, Seventh

Edition. DeVita VT, Hellman S, and Rosenberg SA. (Eds), JB Lippincott Co, Philadelphia, 2005. 20. Chu E. Drug Development. In: DeVita VT, Hellman S, and Rosenberg SA. (Eds), Cancer: Principles and

Practice of Oncology, Seventh Edition, JB Lippincott Co, Philadelphia, 2005. 21. Copur MS, Rose M, Chu E. Miscellaneous Agents. In: DeVita VT, Hellman S and Rosenberg SA. (Eds),

Cancer: Principles and Practice of Oncology, Seventh Edition, JB Lippincott Co, Philadelphia, 2005. 22. Aggarwal S, Chu E. Advances in the chemotherapy of metastatic colorectal cancer, In: Lichtman S. (Ed),

Colorectal Cancer in the Elderly Patient: Assessment and Treatment, CMP Healthcare Media, Manhasset, NY, 69-88, 2005.

23. Chu E, Mota A, Bromberg M, Copur MS, Harrold LJ, Tiedemann D, Roy S, Fogarasi M.

Chemotherapeutic and Biologic Drugs. In: Chu E and DeVita VT. (Eds), Physician’s Cancer Chemotherapy Drug Manual 2005, Jones and Bartlett Publishers, 21-373, Sudbury, MA, 2005.

24. Noronha V, Mota A, Fogarasi M, Tiedemann D, Chu E. Guidelines for chemotherapy and dosing

modifications. In: Chu E and DeVita VT. (Eds), Physician’s Cancer Chemotherapy Drug Manual 2005, Jones and Bartlett Publishers, 375-392, Sudbury, MA, 2005.

25. Chu E, Noronha V, Roy S, Mota A, Nabbout N, Harrold LJ, Tiedemann D, Fogarasi M, Copur MS.

Common chemotherapy regimens in clinical practice. In: Chu E and DeVita VT. (Eds), Physician’s Cancer Chemotherapy Drug Manual 2005, Jones and Bartlett Publishers, 393-487, Sudbury, MA, 2005.

26. Copur MS, Harrold LJ, Kim R, Chu E. Antiemetic agents for the treatment of chemotherapy-induced

nausea and vomiting. In: Physician’s Cancer Chemotherapy Drug Manual 2005, Chu E and DeVita VT. (Eds). 489-529, Jones and Bartlett Publishers, Sudbury, MA, 2005.

27. Saif MW, Kim R, Chu E. First-line treatment of advanced colorectal cancer. In: Colorectal Cancer –

Evidence-Based Chemotherapy Strategies. Saltz LB. (Ed). Humana Press, 2006. 28. Chu E, Sartorelli AC. Cancer Chemotherapy. In: Basic and Clinical Pharmacology, 10th Edition. Katzung

BG. (Ed), McGraw-Hill, New York, NY, 2007. 29. Lee JJ, Chu E. Role of biologic agents in adjuvant therapy, In: Chu E (Ed), A multidisciplinary approach

to the treatment of early colorectal cancer, CMP Healthcare Media, Manhasset, NY, 97-112, 2007. 30. McGowan MM, Chu E, Lee J. Neoadjuvant Combined Modality Approaches for Locally Advanced Rectal

Cancer, In: Chu E (Ed), A multidisciplinary approach to the treatment of early colorectal cancer, CMP Healthcare Media, Manhasset, NY, 113-130, 2007.

31. Saif MW, Chu E. Antimetabolites. In: Cancer: Principles and Practice of Oncology, Eighth Edition. DeVita

VT, Lawrence T, and Rosenberg SA. (Eds), JB Lippincott Co, Philadelphia, 2008. 32. Lee JJ, McGowan MM, Chu E. Biology of Colorectal Cancer, In: Chu E (Ed), New treatment strategies

for metastatic colorectal cancer, CMP Healthcare Media, Manhasset, NY, 1-19, 2008. 33. Chu E, DeVita VT. Principals of Chemotherapy. In: DeVita VT, Lawrence T, and Rosenberg SA. (Eds),

Cancer: Principles and Practice of Oncology, Eighth Edition, JB Lippincott Co Philadelphia, 2008. 34. Chu E, Sartorelli AC. Cancer Chemotherapy. In: Basic and Clinical Pharmacology, 11th Edition. Katzung

BG. (Ed), McGraw-Hill, New York, NY, 935-952, 2009. 35. Saif MW, Chu E. Antimetabolites. In: Cancer: Principles and Practice of Oncology. 9th Edition. DeVita VT,

Lawrence T, and Rosenberg SA. (Eds). JB Lippincott Co, Philadelphia, 393-401, 2011. 36. Chu E, DeVita VT. Principles of Chemotherapy. In: Cancer: Principles and Practice of Oncology, 9th

Edition. DeVita VT, Lawrence T, and Rosenberg SA. (Eds). JB Lippincott Co, Philadelphia, 312-321, 2011.

37. Chu E. Principles of Medical Oncology. In: Hoff P, Chammas R, Novis Y, Katz A, and Filho V. (Eds).

Oncology, First Edition, Editora Atheneu, Sao Paulo, 2010. 38. Chu E, Sartorelli AC. Cancer Chemotherapy. In: Basic and Clinical Pharmacology, 12th Edition. Katzung

BG. (Ed), McGraw-Hill, New York, NY, 949-975, 2012. 39. Lee JJ, Kim TW, and Chu, E. Global Cancer Care for Colorectal Cancer. In: Global Perspectives on

Cancer: Incidence, Care, and Clinical Experience, 2014. Miller K and Simon M. (Eds), 2015. 40. Chu E, Sartorelli AC. Cancer Chemotherapy. In: Basic and Clinical Pharmacology, 13th Edition. Katzung

BG. (Ed), McGraw-Hill, New York, NY, 2014. 41. Saif MW, Chu E. Antimetabolites. In: Cancer: Principles and Practice of Oncology. 10th Edition. DeVita

VT, Lawrence T, and Rosenberg SA. (Eds), JB Lippincott Co, Philadelphia, 2014. 42. Lee JJ, Goel G, and Chu E. Adjuvant Chemotherapy of Colon Cancer. In: Multidisciplinary Management

of Gastrointestinal Cancers. Sun W. (Ed). World Scientific, Singapore. 2017. 43. Chu E. Cancer Chemotherapy. In: Basic and Clinical Pharmacology, 14th Edition. Katzung BG. (Ed),

McGraw-Hill, New York, NY, in press, 2017. 44. Chu E. Neoplasms of the Small and Large Intestine. In: Goldman-Cecil Medicine, 26th Edition. Goldman

L and Schafer A (Eds), Elsevier, New York, NY, in press, 2018. 45. Lee JJ, Chu E. Antimetabolites. In: Cancer: Principles and Practice of Oncology. 11th Edition. DeVita VT,

Lawrence T, and Rosenberg SA. (Eds). JB Lippincott Co, Philadelphia, in press, 2018. 3. Books Edited 1. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual. First Edition, Jones and Bartlett

Publishers, Boston, 2001. 2. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual 2002 Second Edition, Jones and

Bartlett Publishers, Boston, 2002. 3. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual 2003 Third Edition, Jones and

Bartlett Publishers, Boston, 2003. 4. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual 2004 Fourth Edition, Jones and

Bartlett Publishers, Sudbury, MA, 2004. 5. Chu E. Cancer Chemotherapy Pocket Guide 2004, First Edition, Jones and Bartlett Publishers, Sudbury,

MA, 2004. 6. Chu E. Cancer Chemotherapy Pocket Guide 2005, Second Edition, Jones and Bartlett Publishers,

Sudbury, MA, 2005. 7. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual 2005 Fifth Edition, Jones and Bartlett

Publishers, Sudbury, MA, 2005. 8. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual 2006 Sixth Edition, Jones and

Bartlett Publishers, Sudbury, MA, 2006. 9. Chu E. Cancer Chemotherapy Pocket Guide 2006, Third Edition, Jones and Bartlett Publishers, Sudbury,

MA, 2006. 10. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual 2007 Seventh Edition, Jones and

Bartlett Publishers, Sudbury, MA, 2007. 11. Chu E. Cancer Chemotherapy Pocket Guide 2007, Fourth Edition, Jones and Bartlett Publishers,

Sudbury, MA, 2007. 12. Chu E. A multidisciplinary approach to the treatment of early colorectal cancer, CMP Healthcare Media,

Manhasset, NY, 2007. 13. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual 2008 Eighth Edition, Jones and

Bartlett Publishers, Sudbury, MA, 2008. 14. Chu E. New treatment strategies for metastatic colorectal cancer, CMP Healthcare Media, Manhasset,

NY, 2008. 15. Chu E. Cancer Chemotherapy Pocket Guide 2008, Fifth Edition, Jones and Bartlett Publishers, Sudbury,

MA, 2008. 16. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual 2009 Ninth Edition, Jones and

Bartlett Publishers, Sudbury, MA, 2009. 17. Chu E. Cancer Chemotherapy Pocket Guide 2009. Sixth Edition, Jones and Bartlett Publishers, Sudbury,

MA, 2009. 18. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual 2010. Tenth Edition, Jones and

Bartlett Publishers, Sudbury, MA, 2010. 19. Chu E. Cancer Chemotherapy Pocket Guide 2010. Sixth Edition, Jones and Bartlett Publishers, Sudbury,

MA, 2010. 20. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual 2011. Eleventh Edition, Jones and

Bartlett Publishers, Sudbury, MA, 2011.

21. Chu E. Cancer Chemotherapy Pocket Guide 2011. Seventh Edition, Jones and Bartlett Publishers,

Sudbury, MA, 2011. 22. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual 2012. Twelfth Edition, Jones and

Bartlett Publishers, Sudbury, MA, 2012. 23. Chu E. Cancer Chemotherapy Pocket Guide 2012. Eighth Edition, Jones and Bartlett Publishers,

Sudbury, MA, 2012. 24. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual 2013. Thirteenth Edition, Jones and

Bartlett Publishers, Sudbury, MA, 2013. 25. Chu E. Cancer Chemotherapy Pocket Guide 2013. Ninth Edition, Jones and Bartlett Publishers, Sudbury,

MA, 2013. 26. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual 2014. Fourteenth Edition, Jones and

Bartlett Publishers, Sudbury, MA, 2014. 27. Chu E. Cancer Chemotherapy Pocket Guide 2014. Tenth Edition, Jones and Bartlett Publishers, Sudbury,

MA, 2014. 28. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual 2015. Fifteenth Edition, Jones and

Bartlett Publishers, Sudbury, MA, 2015. 29. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual 2016. Sixteenth Edition, Jones and

Bartlett Publishers, Sudbury, MA, 2016. 30. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual 2017. Seventeenth Edition, Jones

and Bartlett Publishers, Sudbury, MA, 2017. 31. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual 2018. Eighteenth Edition, Jones and

Bartlett Publishers, Sudbury, MA, 2018. 32. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual 2019. Nineteenth Edition, Jones and

Bartlett Publishers, Sudbury, MA, 2019. 33. Chu E, DeVita VT. Physician’s Cancer Chemotherapy Drug Manual 2020. Twentieth Edition, Jones and

Bartlett Publishers, Sudbury, MA, in press. 4. Other Publications (Commentaries, Editorials, Education) 1. Chu E, Politi P. American Cancer Society Textbook of Clinical Oncology. Book Review, J Natl Cancer

Inst. 1992; 84:198. 2. Chu E. The evolving paradigm: advances in the chemotherapeutic management of metastatic colorectal

cancer. Oncology Special Edition. 2003; 1:92-112. 3. Chu E. Oral chemotherapy comes of age. Clin Colorectal Cancer. 2000; 2:75-76. 4. Copur MS, Chu E. Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer.

2001; 1:179-180. 5. Chu E. Thymidylate synthase as a molecular biomarker. Clin Colorectal Cancer. 2001; 1:136-137. 6. Chu E. Targeting metastasis and angiogenesis. Clin Colorectal Cancer. 2001; 1:200. 7. Maung K, Lee D, DeGrendele HC, Schilsky R, Chu E, Jain VK, Copur S. Highlights from: 27th

congress of the European Society for Medical Oncology, Nice, France October 2002. Clin Colorectal Cancer. 2002; 2:140-145.

8. Chu E. Lessons learned from the Saltz and Mayo Clinic regimens. Clin Colorectal Cancer. 2002; 2:13-14. 9. Chu E. Oxaliplatin: a welcome addition to our therapeutic armamentarium. Clin Colorectal Cancer. 2002;

2:72. 10. Johnson L, Chu E. Lack of benefit of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer

with microsatellite instability. Clin Colorectal Cancer. 2002; 2:146-148. 11. Chu E. A novel methionine-based mechanism for controlling the expression of thymidylate synthase.

Cancer Biol Ther. 2003; 2:370-371. 12. Chu E. The role of stool DNA analysis in the early detection and screening of colorectal cancer. Clin

Colorectal Cancer. 2003; 3:1-2. 13. Chu E. Validation of the role of angiogenesis as a chemotherapeutic target. Clin Colorectal Cancer.

2003; 3:74-75. 14. Chu E. The epidermal growth factor receptor signaling pathway as a chemotherapeutic target. Clin

Colorectal Cancer. 2003; 2:202-203. 15. Chu E. Bevacizumab targeted therapy; validation of angiogenesis as a key target for advanced colorectal

cancer. Clin Colorectal Cancer. 2004; 4:16. 16. Chu E. Cetuximab targeted therapy: a new treatment paradigm for advanced colorectal cancer. Clin

Colorectal Cancer. 2004; 3:205. 17. Chu E. Adjuvant therapy: new treatment options. Clin Colorectal Cancer. 2004; 4:219-220. 18. Chu E. Dihydopyrimidine dehydrogenase: a critical molecular biomarker for 5-fluorouracil toxicity. Clin

Colorectal Cancer. 2004; 4:150. 19. Chu E. Making sense out of antisense thymidylate synthase. Clin Colorectal Cancer. 2005; 5:12. 20. Chu E. New developments at the American Society of Clinical Oncology 2005 Gastrointestinal Cancers

Symposium. Clin Colorectal Cancer. 2005; 4:358. 21. Chu E. The development of the FOLFOX regimens as a treatment standard of advanced colorectal

cancer. Clin Colorectal Cancer. 2005; 4:292. 22. Chu E. Lessons learned from mother nature. Clin Colorectal Cancer. 2005; 5:232. 23. Chu E. Introduction: Emerging therapies with epidermal growth factor receptor-targeted agents in

colorectal cancer. Clin Colorectal Cancer. 2005; 5:S60-61. 24. Chu E. Adjuvant therapy: new treatment options with oxaliplatin-based chemotherapy. Clin Colorectal

Cancer. 2005; 5:80-81. 25. Chu E. Panitumumab: a new anti-EGFR antibody for the treatment of advanced colorectal cancer. Clin

Colorectal Cancer. 2006; 6:13. 26. Chu E. Colorectal cancer awareness month. Clin Colorectal Cancer. 2006; 5:389. 27. Chu E. Clinical colorectal cancer: new advances in screening. Clin Colorectal Cancer. 2006; 5:312. 28. Chu E. The role of a drug holiday: even patients with cancer need a vacation. Clin Colorectal Cancer.

2006; 6:182. 29. Chu E. 2006 – The year in review. Clin Colorectal Cancer. 2007; 6:256-257. 30. Chu E. Targeted therapy. Clin Colorectal Cancer. 2007; 6:336. 31. Chu E. The role of a drug holiday: revisited. Clin Colorectal Cancer. 2007; 6:554-555. 32. Chu E. Equal opportunity for the elderly. Clin Colorectal Cancer. 2008; 7:356. 33. Chu E. Sequential versus combination therapy: where are we? Clin Colorectal Cancer. 2008; 7:295. 34. Gibson TB, Grothey E, Chu E. Highlights from: The 44th Annual Meeting of the American Society of

Clinical Oncology, Chicago, IL; May 30-June 3, 2008. Clin Colorectal Cancer. 2008; 7:33-239. 35. Chu E. Dual biologic therapy in the first-line mCRC setting: implicatons of the CAIR02 study. Clin

Colorectal Cancer. 2008; 7:26. 36. Chu E. Molecular biomarker development for anti-EGFR therapy: moving beyond EGFR expression. Clin

Colorectal Cancer. 2008; 7:162. 37. Chu E. Recent developments on the integration of biologic agents with cytotoxic chemotherapy in the

treatment of advanced colorectal cancer. Clin Colorectal Cancer. 2008; 7(Suppl 2):S46. 38. Chu E. Clinical colorectal cancer, “2008 - the year in review.” Clin Colorectal Cancer. 2009; 8:9-10. 39. Chu E. Colorectal cancer awareness month. Clin Colorectal Cancer. 2009; 8:71. 40. Chu E. Expanding our horizons: colorectal cancer and other gastrointestinal malignancies. Clin

Colorectal Cancer. 2009; 8(3):127. 41. Chu E. Colorectal cancer screening and early detection: 2010. Clin Colorectal Cancer. 2010; 9:1. 42. Chu E. Integration of targeted therapies with cytotoxic chemotherapy in the treatment of colorectal

cancer. Clin Colorectal Cancer. 2010; 9(Suppl 1):S1. 43. Chu E. Advances in colorectal cancer. The Cancer Journal: Journal of Principles and Practice of

Oncology. 2010;16:195.

44. Chu E. IGF-1R as a target in cancer therapy. Oncology 2011;25:538-539. 45. Chu E. A decade of Clinical Colorectal Cancer. Clin Colorectal Cancer. 2011:10:217. 46. Chu E. Molecular profiling and personalized medicine. Cancer J. 2011;17:69-70. 47. Lee, JJ and Chu E. Personalized medicine in the adjuvant chemotherapy of stage II colon cancer – are

we there yet? Oncology 2013;27:756-758. PMID: 24133821. 48. Chu E. Personalized medicine and anti-EGFR antibody therapy in the treatment of metastatic colorectal

cancer: KRAS and beyond. Oncology 2014;28:96. PMID: 24701695. 49. Chu E. The practical implications of tumor heterogeneity. Oncology 2014, in press. 50. Chu E and Sessa C. Anticancer agents. ESMO/ASCO recommendations for a global curriculum in

medical oncology – edition 2016. Ann Oncol. 2016;27:1378-81. 51. Dittrich C, Kosty M,…. Chu E. et al. ESMO/ASCO recommendations for a global curriculum in medical

oncology edition 2016. ESMO Open. 2016;29:1(5):e000097. eCollection 2016. 52. Lee JJ and Chu E. Therapeutic drug monitoring of 5-FU in the personalized treatment of metastatic

colorectal cancer. Clin Colorectal Cancer. 2016;78:447-464. PMID: 27217046. 53. Lee JJ and Chu E. Adjuvant chemotherapy of stage II colon cancer: the debate goes on. J Oncol

Practice 2017;13:245-246. PMID: 28399385. 54. ESMO/ASCO Global Curriculum Working Group. ESMO/ASCO recommendations for a global curriculum

in medical oncology – edition 2016. Ann Oncol. 2016;27:1378-1381. PMID: 27457308.

PATENTS 1. Patent #9096853. Chu E, Schmitz JC, and Gmeiner W. Modified siRNA molecules

incorporating 5-fluoro-2’-deoxyuridine residues to enhance cytotoxicity. Issued 8/4/2015.

PROFESSIONAL ACTIVITIES TEACHING: 1996-2010 Lecturer, Oncology Module for 2nd Year Medical Students, Yale Univ School of Medicine 1996-2010 Lecturer, Pharmacology 501b Course (Principles in Pharmacology) for

2nd Year Medical Students, Yale Univ School of Medicine 1996-2010 Lecturer and Group Leader, Pharmacology 501b “Workshop in Cancer Therapeutics”,

2nd Year Medical Students, Yale Univ School of Medicine 1996-2010 Lecturer, Pharmacology 518b Course (Current Topics in Cancer and Viral Therapy)

for Graduate Students, Yale Univ School of Medicine 1996-2010 Lecturer, Pharmacology 504a Course (Principles of Pharmacology) for Graduate Students, Yale Univ School of Medicine

1996-2010 Lecturer, Pharmacology 502b Course (Seminars in Pharmacology) for Graduate Students, Yale Univ School of Medicine 1996-2010 Lecturer, Medical Oncology Fellowship Lecture Series, Yale Univ School of Medicine 1996-2010 Lecturer, Noontime Internal Medicine Housestaff Lecture Series, Yale Univ School of Medicine 1997-2006 Lecturer, Pathology 650b Course (Cellular and Molecular Biology of Cancer) for Graduate

Students, Yale Univ School of Medicine 2005-2007 Course Director and Lecturer, Oncology Module for 2nd Year Physician’s Associate Students, Yale Univ School of Medicine 2007-2010 Lecturer, Oncology Module for 2nd Year Physician’s Associate Students, Yale Univ School of Medicine 2010 Lecturer, Hematology-Oncology Fellowship Lecture Series, Univ of Pittsburgh School of

Medicine 2010 Lecturer, Cancer Biology and Therapeutics Course (MSCMP3710/MSPHL3310), Integrated

Program in Biomedical Sciences and Depts of Pathology and Pharmacology, Univ of Pittsburgh School of Medicine

2011-present Lecturer, MED5222 Hematology Course for 2nd Year Medical Students, Univ of Pittsburgh School of Medicine

2011-present Lecturer, Cancer Biology and Therapeutics Course (MSCMP3710/MSPHL3310), Integrated Program in Biomedical Sciences and Depts of Pathology and Pharmacology, Univ of Pittsburgh School of Medicine

2011-present Lecturer, Hematology-Oncology Fellowship Lecture Series, Univ of Pittsburgh School of Medicine

2012-present Lecturer, MED5715 Neoplasia Course for 4th Year Medical Students, Univ of Pittsburgh School of Medicine

2012-present Lecturer, MSCMP3790 Basics of Personalized Medicine Course for Graduate Students, Univ of Pittsburgh School of Medicine

SUPERVISION OF PRE- AND POST-DOCTORAL STUDENTS AND CLINICAL MEDICAL ONCOLOGY FELLOWS:

Student Name

PreDoc or PostDoc

Training Period

Previous Institution

Degree/ Year

Awarded

Title of

Research Project

Source of Support

Chris Takimoto

Postdoc clinical oncology fellow

90-93 Yale University Ph.D. Translation regulation of DHFR

NIH/NCI

Lorrin Yee Postdoc clinical oncology fellow

89-92 UCLA M.D. Molecular pharmacology of antimetabolites

NIH/NCI

Keisuke Aiba


90-93 Univ of Tokyo, Japan

M.D. Regulation of thymidylate synthase; 5-FU action

NIH/NCI

Sitki Copur Postdoc clinical oncology fellow

91-94 Ankara Med. School,Turkey

M.D. Regulation of TS NIH/NCI

Teji Takechi Postdoc 92-95 Univ. of Tokyo, Japan

Ph.D. Regulation of TS NIH/NCI

Nobu Mizunuma


92-96 Hokkaido Univ. Med School, Japan

M.D. Regulation of TS NIH/NCI

Pedro Politi Postdoc clinical oncology fellow

89-92 Univ. Buenos Aires, Argentina

M.D. Molecular pharmacology of antimetabolites

NIH/NCI

Andres Canova


97-99 Univ. Buenos Aires, Argentina

M.D. Phase I/II clinical studies of novel agents

VA

Debra Brandt


97-99 Univ of Iowa D.O. Phase I/II clinical studies of novel agents

NIH/NCI

John Schmitz

Postdoc 96-99 Med Univ South Carolina

Ph.D. Regulation of TS by antisense RNA

VA

Jingfang Ju Postdoc 96-99 Univ of Southern California

Ph.D. Regulation of cellular gene expression by thymidylate synthase

NIH/NCI

Xiukun Lin Postdoc 96-99 Peking Union Med College, China

M.D., Ph.D.

Molecular regulation of thymidylate synthase

NIH/NCI

Jun Liu Postdoc 97-99 Peking Med Univ., China

M.D., Ph.D.

Molecular regulation of thymidylate synthase

NIH/NCI

Tian-min Chen

Postdoc 96-99 Brown Univ. M.S. Molecular regulation of thymidylate synthase

NIH/NCI

Leslie Parcels

Postdoc 97-99 Univ. Michigan Ph.D. Regulation of cellular gene expression by thymidylate synthase

NIH/NCI

Rami Sarid Postdoc clinical oncology fellow

98-00 Univ. Arizona Clinical pharmacology, phase I studies of novel compounds

NIH/NCI

Augusto Mota


98-00 Amer. Med. University of Brazil

M.D. Clinical pharmacology of L-nucleoside compounds

NIH/NCI

Miklos Fogarasi


98-01 Univ. Budapest, Hungary

M.D. Clinical pharmacology of antimetabolites, phase I studies of novel compounds

NIH/NCI

Nassim Nabbout


98-01 American Univ,. Lebanon

M.D. Clinical pharmacology of novel anticancer agents

NIH/NCI

Wu Yan Postdoc 00-02 Wuhan Univ, China

Ph.D. Translation regulation of p53 mRNA translation by TS

NIH/NCI

Michael Farrell


01-03 Univ. Rochester M.D., Ph.D.

Regulation of p53 expression by thymidylate synthase

NIH/NCI

Ningwen Tai Postdoc 01-08 Shanghai Inst. of Biochemistry, China

Ph.D. Translational regulation of dihydrofolate reductase

VA

Weiguo Hu Postdoc 04-07 Shanghai Inst. of Biochemistry, China

Ph.D. Translational regulation of thymidylate synthase

VA

Tong Dai Postdoc 04-07 Univ. of Pennsylvania

Ph.D. Regulation of TS expression

NIH/NCI

Yong Zheng Postdoc 04-07 Shanghai Inst. of Biochemistry, China


NIH/NCI

Zheng Wang

Postdoc 07-10 Peking Union Med. College, China


NIH/NCI

Peter Kang Postdoc clinical oncology fellow

05-07 Albert Einstein Medical College

M.D. Clinical pharmacology, phase I studies of novel compounds

NIH/NCI

Margit McGowan


06-08 Philadelphia College of Osteopathic Medicine

D.O. Clinical pharmacology, phase I studies of novel compounds

NIH/NCI

Xiang-yi Li Postdoc 09-11 Univ of Erasmus, Holland

M.D., Ph.D.

Role of miRNAs in regulation of TS expression

NIH/NCI

Ning Wei Postdoc 11- present

Peking Union Medical College, China

Ph.D. Pre-clinical development of novel agents for CRC

Haizhou Liu Postdoc 11- present

Qingdao University of

Ph.D. Development of Chinese herbal

Science and Technology, Chinese Academy of Science, China

medicine in the treatment of CRC

Shaoyu Wu Postdoc 11- present

Ph.D. Role of miRNAS in regulating TS expression and mediating drug resistance in CRC

Marcus Yeh Postdoc 11- present

National Taiwan University Medical School, Taiwan

M.D. Determinants of resistance to TS inhibitor compounds

Zhiyi Zhou Postdoc 13-14 Shanghai University of Traditional Chinese Medicine

M.D. Development of Chinese herbal medicine in the treatment of CRC

Hui Liu Postdoc 13-14 Shanghai University of Traditional Chinese Medicine

M.D. Development of Chinese herbal medicine in the treatment of CRC

Mariel Kerr

Postdoc Internal Medicine Resident

10- present

Univ of Virginia

M.D.

Chinese herbal medicine as a modulator of irinotecan-based chemotherapy

Rushir Choksi

Hematology-Oncology Fellow

10- present

Case Western

M.D.

Clinical development of new agents in GI cancers

Kristin Turner

Predoc 99-00 Cornell Univ.

Development of new approaches to inhibit TS expression

NIH/NCI

Stephen Hayhurst

Predoc 98-00 Yale Univ Novel approaches to inhibit the expression of thymidylate synthase

NIH/NCI

Jonathan Smith

Predoc 98-00 Bates College Novel approaches to inhibit the expression of thymidylate synthase

NIH/NCI

Kara Siegel Predoc 98-00 Columbia Univ, Novel approaches to inhibit the expression of thymidylate

NIH/NCI

synthase

MEMBER OF Ph.D. THESIS COMMITTEES: 1995 Jingfang Ju (outside reviewer, University of Southern California, Biochemistry) 1995 John Schmitz (outside reviewer, Medical University of South Carolina, Pharmacology) 1999 Chris Gaj (Molecular Biochemistry and Biophysics)

Ching Chen Predoc 99-01 Brown Univ Regulation of thymidylate synthase

NIH/NCI

Kara Siegel Predoc 98-00 Columbia Univ Regulation of thymidylate synthase

NIH/NCI

Chris Bimmler

Predoc 01-04 Univ. of CT Novel approaches to inhibit the expression of thymidylate synthase

NIH/NCI

Jose Alex Candelario

Predoc 01-03 Yale University Novel approaches to inhibit the expression of thymidylate synthase

NIH/NCI

Marc Callender

Predoc 02-04 Yale University Development of siRNAs to inhibit TS expression

NIH/NCI

Rebecca Hunter

Predoc MD thesis

04-07 Yale University School of Medicine

Development of novel approaches to inhibit TS expression

NIH/NCI

Alexa Smith Predoc

08-09 Yale University School of Medicine

Study of Chinese herbal medicine in the treatment of GI cancers

Matthew Adler

Predoc 11-12 Univ of Pittsburgh

Study of novel agents for colorectal cancer

Mona Liu Predoc 11-12 Univ of Pittsburgh School of Medicine

Development of Chinese herbal medicines in CRC

Wei Yang Predoc 12- present

Tsinghua/Univ of Pittsburgh School of Medicine

Role of protein kinase D (PKD) signaling in colorectal cancer

Junu Bae Predoc 12-13 Carnegie Mellon University

PKD signaling in colorectal cancer

Hui-Tien Liu Predoc 19-present Taipei Medical University

Development of novel STAT3 inhibitors

2001 Rong Hu (Pharmacology) 2002 Shilpa Patel (Pharmacology) 2002 Helen Seow (Pharmacology) 2002 Eric Johnson (Pharmacology) 2005 Michelle Lin (Pharmacology) 2005 Chloe Atreya (Pharmacology) 2007 Tina Dasgupta (Pharmacology) 2008 Edward Martucci (Molecular Biochemistry and Biophysics) 2009 Jiae Kim (Pharmacology) 2011 Chris Hoimes, D.O. (Biomedical Engineering, Investigative Medicine Program) MEMBER OF GRADUATE TRAINING GRANT PROGRAMS: 1997-2010: Biochemical Aspects of Chemotherapy, Dept. of Pharmacology 1998-2010: Blood Diseases, Dept. of Medicine 1998-2010: Radiation Therapy, Biology, and Physics RESEARCH:

1. GRANT SUPPORT ACTIVE/APPROVED FUNDING: 1. NIH/NCI: UM1 CA186690 (P.I.) 4/1/14 – 2/28/20 2.0 cm Effort

Title: Early clinical trials of new anticancer agents with phase I emphasis. The major goal of this project is to design and develop early-phase clinical trials of novel anticancer agents with incorporation of pharmacokinetic and pharmacodynamic biomarkers. Role: P.I.

2. NIH/NCI: UM1 CA186690 (P.I.) 4/1/15 – 2/28/20 2.0 cm Effort

Title: Early clinical trials of new anticancer agents with phase 2 emphasis. The major goal of this project is to design and develop phase 2 clinical trials of novel anticancer agents and combination regimens with incorporation of translational pharmacodynamic biomarkers. Role: P.I.

3. NIH/NCI: UM1 CA186690 - supplement (P.I.) 8/1/18 – 2/28/20 0.1 cm Effort

Title: Drug interactions with iohexol The major goal of this supplement is to evaluate the potential of iohexol to be a perpetrator of drug-drug interactions. Role: P.I.

4. NIH/NCI: UM1 CA186690 - supplement (P.I.) 4/1/15 – 2/28/20 0.1 cm Effort

Title: PK of iohexol and carboplatin. The major goal of this supplement is to support the pharmacokinetic evaluation of carboplatin and iohexol in ongoing clinical trials and to define the potential relationship between kidney function and carboplatin clearance. Role: P.I.

5. NIH/NCI: P30 CA147904 (Ferris, P.I.) 8/1/15 – 7/30/20 1.2 cm Effort

Title: Comprehensive Cancer Center Core Support Grant. The major goal of this project is to provide support and oversight over the research efforts of the Molecular Therapeutics Drug Discovery Research Program of the University of Pittsburgh Cancer Institute. Role: Co-Leader, Cancer Therapeutics Research Program.

6. NIH/NCI: P30 CA147904 (Ferris, P.I.) 8/1/15 – 7/30/20 1.2 cm Effort

Title: Comprehensive Cancer Center Core Support Grant. The major goal of this project is to provide administrative support and oversight over the clinical and translational research efforts of the University of Pittsburgh Cancer Institute. Role: Deputy Director.

7. NIH/NCI: T32 CA147904 (P.I.) 9/1/15 – 8/31/20 1.2 cm Effort

Title: Training Program in Cancer Therapeutics. The major goal of this training grant is to train the next generation of physician-scientists with specific expertise in cancer therapeutics. The training of physician-scientists in both pre-clinical and clinical/translational science will greatly advance the field of cancer therapeutics with the eventual goal of developing novel agents and treatment regimens for the treatment of human cancer. Role: P.I.

8. NIH/NCI: R01 CA197103 (Schenker, P.I.) 4/1/16 – 3/31/21 0.6 cm Effort

Title: A Cluster Randomized Trial of a Primary Palliative Care Intervention (CONNECT) for Patients with Advanced Cancer. The objective of this project is to conduct a cluster randomized trial of 672 patients with advanced cancer and their caregivers receiving care at 16 community oncology clinics, assessing the impact of the CONNECT intervention on patient and caregiver 3-month outcomes and health care utilization. Role: Co-Investigator

9. NIH/NCI: R01CA235730 (Schenker, P.I.) 3/01/2019 – 2/29/24 0.6 cm Effort

Title: Patient-centered and Efficacious Advanced Care Planning in Cancer: the PEACe Comparative Effectiveness Trial. The objective of this project is to conduct a single-blind, patient-level randomized trial of 400 patients with advanced cancer and 300 of their family caregivers to compare the effectiveness of in-person, facilitated ACP versus web-based ACP. The Hillman Cancer Center and 5 community oncology clinics are involved, which represents a mix of academic and community practice models. Role: Co-Investigator

PRIOR FUNDING: 1. NIH/NCI: R01-CA75712 12/1/97 - 11/30/08 1.2 cm Effort Direct Costs: $200,000/year Title: Molecular Basis for TS Translational Regulation.

The goal of this project was to study the regulation of expression of thymidylate synthase and to define the molecular elements underlying the interaction between thymidylate synthase and its target TS mRNA.

Role: P.I. 2. NIH/NCI: R01-CA89300 12/1/02 – 11/30/08 1.2 cm Effort Direct Costs: $100,000/year Title: Novel Non-inducible Thymidylate Synthase Inhibitors.

The goal of this project was to develop novel inhibitor compounds of thymidylate synthase that will effectively inhibit enzyme activity but not allow for the induction of expression of TS. These agents will be developed as novel molecules to treat human colorectal cancer.

Role: Co-P.I. 3. NIH/NCI: R01-CA82897-10 4/1/98 – 3/31/10 1.2 cm Effort

Title: Molecular Basis for Translational Regulation. The goal of the project is to characterize the translational regulation of dihydrofolate reductase and to define the molecular elements involved in the interaction between dihydrofolate reductase and its target DHFR mRNA. Role: P.I.

4. State of Connecticut, Dept. of Public Health 4/1/08 – 8/31/10 1.2 cm Effort Title: Development of a statewide clinical trials network The major goal of the project is to develop a statewide clinical trials network that has the Yale Cancer Center has the main referral site working closely with community oncology practices. Role: P.I.

5. VA Merit Review, Dept. of Veterans Affairs 10/1/97 – 9/30/12 1.2 cm Effort

Title: siRNAs as novel therapeutic agents for cancer chemotherapy The major goal of the project is to investigate the role of small-interfering (si) RNAs as novel therapeutic agents for cancer chemotherapy in the treatment of colorectal cancer. Specifically. siRNAs will be developed as novel therapeutic agents to overcome development of drug resistance in response to treatment with TS inhibitor compounds. Role: P.I.

6. NIH/NCI: U01 CA099168 (P.I.) 3/1/09 – 2/28/14 1.6 cm Effort Title: Early clinical trials of new anticancer agents with phase I emphasis. The major goal of this project is to design and develop early-phase clinical trials of novel anticancer agents with incorporation of pharmacokinetic and pharmacodynamic biomarkers. Role: P.I.

7. NIH/NCI: P01-CA154295 (Chu, Co-P.I.) 9/15/11 – 8/31/17 3.3 cm Effort

Title: Chinese Herbal Medicine as a Novel Paradigm for Cancer Chemotherapy. The goal of this interdisciplinary, clinical- and translational-based program project grant is to investigate the role of a novel Chinese herbal medicine PHY-906 as a modulator of cancer chemotherapy in the treatment of metastatic colorectal cancer. Role: Co-P.I.

2. SEMINARS AND INVITED LECTURESHIPS RELATED TO RESEARCH Jan. 24, 2008 “Moving Anti-EGFR Antibodies into the Front-Line Treatment of Advanced

Colorectal Cancer”, ASCO GI 2008 Symposium, Orlando, FL Jan. 25, 2008 “Potentially Curable Metastatic Disease in Colorectal Cancer: Neoadjuvant

Approach to Liver-Limited Disease”, ASCO GI 2008 Symposium, Orlando, FL Feb. 23, 2008 “Integration of Biologic Agents and Chemotherapy for Metastatic Colorectal

Cancer”, Current Trends in GI Malignancies (Program Chairman), Washington, DC.

March 1, 2008 “Optimizing Chemotherapy for Metastatic Colorectal Cancer”, Current Trends in

GI Malignancies (Program Chairman), New York, NY. March 3, 2008 “New Concepts in Cancer Drug Development”, European Clinical Trials

Symposium, Athens, Greece.

March 15, 2008 “Role of Biologic Agents in the Treatment of Metastatic Colorectal Cancer”, Current Trends in GI Malignancies (Program Chairman), Boston, MA.

April 5, 2008 “Looking to the Future with Capecitabine-Based Regimens for Advanced

Colorectal Cancer”, European GI Congress, Prague, Czech Republic. April 24, 2008 “Advances in Drug Development – From Bench to Bedside and Back”, Huntsman

Cancer Institute Grand Rounds, Salt Lake City, UT. May 20, 2008 “Key Issues in Metastatic Colorectal Cancer”, ASCO 2008 Satellite Symposium

(Program Chair), Chicago, Il. June 28, 2008 “Oxaliplatin-Based Regimens plus Avastin in the Treatment of mCRC”. Latin

American Oncology Summit, Buenos Aires, Argentina. June 28, 2008 “Treatment Advances in Metastatic Gastric Cancer”, Latin American Oncology

Summit, Buenos Aires, Argentina. Aug. 26, 2008 “Cancer Pharmacology I, II, and III”, George Washington University - Medical

Oncology Board Review Course, Washington, D.C. Sept. 24, 2008 “Cancer Pharmacology I, II, and III”, MD Anderson Cancer Center - Medical

Oncology Board Review Course, Houston, TX. Oct. 3, 2008 “New Advances in the Treatment of Metastatic Colorectal Cancer”. 1st

International GI Oncology Congress, Sao Paulo, Brazil. Oct. 16-18, 2008 7th International Colorectal Cancer Congress (Program Chairman), Aventura, FL. Feb. 27, 2009 “Update on Treatment Advances for Colorectal Cancer, 6th Annual City of Hope

Conference on GI Malignancies, Kona, HI. March 7, 2009 “Update on ASCO GI 2009”, GI Cancer Expert Forum (Program Co-Chairman),

Lisbon, Portugal. March 8, 2009 “Continuum of Care Approach for Metastatic Colorectal Cancer”, GI Cancer Expert

Forum (Program Co-Chairman), Lisbon, Portugal. March 14, 2009 “Integration of Biologic Agents with Cytotoxic Chemotherapy for Metastatic

Colorectal Cancer”, GI Cancer Expert Forum (Program Chairman), New York, NY. March 19, 2009 “KRAS Status and Efficacy of Anti-EGFR Antibody Therapy”, 8th Annual Japan

Society of Medical Oncology Meeting, ASCO-JSMO Joint Symposium, Nagoya, Japan.

March 20, 2009 “New Era of Personalized Medicine in the Treatment of Colorectal Cancer”, 8th

Annual Japan Society of Medical Oncology Meeting, Keynote Symposium, Nagoya, Japan.

April 18, 2009 “Coupled Diagnostics and Biologically Targeted Therapeutics in the Treatment of

Colorectal Cancer”, American Association for Cancer Research (AACR) 2009 Annual Meeting, Educational Symposium, Denver, CO.

May 31, 2009 “Should Chemotherapy Plus a Targeted Agent be the New Standard for Initial

Management of Metastatic Colorectal Cancer”, ASCO 2009 Satellite Symposium - Dilemmas in Colorectal and Gastric Cancer Management, Orlando, FL.

June 13, 2009 “Management of GI Malignancies”, Emerging Trends in Oncology, New York

Academy of Sciences, New York, NY. June 26, 2009 “Update on Treatment Advances in Colorectal Cancer”, Post-ASCO 2009 Meeting

(Program Chairman), New Haven, CT. Aug. 27, 2009 “PHY906 as a Modulator of Irinotecan Chemotherapy in the Treatment of

Metastatic Colorectal Cancer”, 8th International Meeting of the Consortium for Globalization of Chinese Medicine, Nottingham, England.

Sept. 17, 2009 “Development of Chinese Herbal Medicine in Cancer Therapy: Where East Meets

West”, University of Miami Sylvester Cancer Center Professors Rounds, Miami, FL.

Sept. 24, 2009 “Cancer Pharmacology I, II, and III”, MD Anderson Cancer Center - Medical

Oncology Board Review Course, Houston, TX. Oct. 12, 2009 “Cancer Pharmacology I, II, and III”, George Washington University - Medical

Oncology Board Review Course, Washington, DC. Oct. 22, 2009 “2009 Update on the Treatment of Advanced Colorectal Cancer”, Ariake Cancer

Center Grand Rounds, Tokyo, Japan. Oct. 24, 2009 “Integration of Biologic Agents with Oral Chemotherapy in the Treatment of

Advanced Colorectal Cancer”, 47th Annual Japan Society of Clinical Oncology (JSCO) Meeting, JSCO Symposium, Yokohama, Japan.

Nov. 12, 2009 “Treatment Strategies for Metastatic Colorectal Cancer”, Albert Einstein College of

Medicine Grand Rounds, New York, NY. Dec. 18, 2009 “Chinese Herbal Medicine as a Modulatory of Cancer Chemotherapy in the

Treatment of Metastatic Colorectal Cancer”, University of Texas Southwestern Cancer Center Grand Rounds, Dallas, TX.

March 1, 2010 “Development of Chinese Herbal Medicine in Cancer Therapy”, University of

Pittsburgh Cancer Institute, Pittsburgh, PA. March 13, 2010 “Treatment of Stage III Colon Cancer: 2010”, Current Trends in GI Malignancies

(Program Chairman), New York, NY. March 17, 2010 “Integration of Anti-EGFR Therapy in the Treatment of Advanced Colorectal

Cancer”, Ariake Cancer Center-National Foundation for Cancer Research Grand Rounds, Tokyo, Japan.

March 18, 2010 “US Treatment Guidelines for First-Line Metastatic Colorectal Cancer”, 8th Annual

Japan Society of Medical Oncology Meeting, JSMO-ASCO Joint Symposium, Tokyo, Japan.

June 26, 2010 “Update on Treatment of Colorectal Cancer”, 2nd Annual Yale ASCO Review

2010 (Program Chairman), Norwalk, CT. Sept. 22, 2010 “Cancer Pharmacology I, II, and III”, MD Anderson Cancer Center - Medical

Oncology Board Review Course, Houston, TX. Oct. 10, 2010 “Cancer Pharmacology I, II, and III”, George Washington University - Medical

Oncology Board Review Course, Washington, DC. Dec. 12, 2010 “New Advances in the Adjuvant Treatment of Early-Stage Colon Cancer”, Keynote

Address, Taiwan Society of Colon and Rectal Surgeons Annual Meeting, Taipei, Taiwan.

Dec. 13, 2010 “Integration of Biologic Agents in the Treatment of Metastatic Colorectal Cancer”,

National Taiwan University Cancer Center Grand Rounds, Taipei, Taiwan. Jan.19, 2011 “Current Perspectives in the Adjuvant Treatment of Colon Cancer: Clinical Outcomes in the

Elderly”, ASCO GI Expert Panel Meeting, 2011 Gastrointestinal Cancers Symposium, San Francisco, CA.

March 30, 2011 “An Update on the Treatment of Metastatic Colorectal Cancer”, University of

Pittsburgh Cancer Institute Grand Rounds, Pittsburgh, PA. July 9, 2011 “Chinese Herbal Medicine in the Treatment of GI Cancer, China-US Symposium in

Cancer and Chinese Herbal Medicine, Beijing, China. July 15, 2011 “Adjuvant Chemotherapy of Early-Stage Colon Cancer”, Society of Mexico

Oncology Annual Forum, San Miguel, Mexico. Sept. 12, 2011 “Cancer Pharmacology I, II, and III”, George Washington University - Medical

Oncology Board Review Course, Washington, DC. Sept. 17, 2011 “Update on Treatment of Colorectal Cancer”, UPCI ASCO Review 2011 (Program

Chairman), Pittsburgh, PA. Sept. 20, 2011 “Cancer Pharmacology I, II, and III”, MD Anderson Cancer Center - Medical

Oncology Board Review Course, Houston, TX. Sept. 24, 2011 “Update in Colon Cancer”, Updates in Hematology and Oncology, University of

Minnesota Masonic Cancer Center, Minneapolis, MN. Oct. 6, 2011 “Chinese Herbal Medicine in the Treatment of Colorectal Cancer: Where East

Meets West”, Science2011 Symposium, University of Pittsburgh School of Medicine, Pittsburgh, PA.

Oct. 29, 2011 “Personalized Medicine in the Treatment of Colorectal Cancer”, 49th Annual

Japan Society of Clinical Oncology (JSCO) Meeting, JSCO Symposium, Nagoya, Japan.

Nov. 16, 2011 “Chinese Herbal Medicine as a Modulator of Chemotherapy in the Treatment of

Colorectal Cancer”, University of Pittsburgh School of Medicine, Dept of Medicine

Grand Rounds, Pittsburgh, PA. Feb. 3, 2012 “Personalized Treatment in Cancer: A Long Day’s Journey Into Night”. 2nd Lung

Cancer Network – From Bench to the Bedside, Athens, Greece. May 26, 2012 “Treatment of Liver-Limited Metastatic Colorectal Cancer”, ASCO 2012 Satellite

Symposium–New Developments in the Treatment of mCRC (Program Co-Chair), Chicago, IL.

May 27, 2012 “Therapeutic Drug Monitoring in the Treatment of Metastatic Colorectal Cancer”,

ASCO 2012 Satellite Symposium, Chicago, IL. Aug. 22, 2012 “Development of Chinese Herbal Medicine in the Treatment of Human Diseases”,

11th International Meeting of the Consortium for Globalization of Chinese Medicine, Macau, China.

Sept. 3, 2012 “Cancer Pharmacology I, II, and III”, George Washington University - Medical

Oncology Board Review Course, Washington, DC. Sept. 12, 2012 “Cancer Pharmacology I, II, and III”, MD Anderson Cancer Center - Medical

Oncology Board Review Course, Houston, TX. Sept. 22, 2012 “Update on Treatment of Colorectal Cancer”, UPCI ASCO Review 2012 (Program

Chairman), Pittsburgh, PA. Oct. 11, 2012 “Update on Treatment Options for Metastatic Colorectal Cancer”, 32nd Annual

Cancer Symposium, Youngstown, Ohio. Nov. 5, 2012 “Clinical Development of Chinese Herbal Medicine in Cancer Treatment: PHY906

as a Paradigm”, China-US Symposium on the State-of-the-Art of Cancer Research and Future Directions for Global Collaboration, Beijing, China.

Jan. 19, 2013 “Development of Chinese Herbal Medicine in Cancer Treatment: Where East

Meets West”, Chao Family Healthcare Conference, Irvine, CA. March 16, 2013 “Pharmacoeconomics and Finite Budgets: Allocation of Funds for the Treatment of

Metastatic Colorectal Cancer?”, EGFR Oncology Network Annual Meeting, Berlin, Germany.

April 20, 2013 “Optimizing Treatment Sequence for Metastatic Colorectal Cancer?”, 4th Annual

Meeting of Taiwan Society of Coloprocotology, Taipei, Taiwan. Aug. 19, 2013 “Cancer Pharmacology I, II, and III”, George Washington University - Medical

Oncology Board Review Course, Washington, DC. Aug. 23, 2013 “Personalized Medicine Strategies in the Treatment of Metastatic Colorectal

Cancer”, Asan Cancer Center Grand Rounds, Seoul, South Korea. Aug. 24, 2013 “2013 Update on the Treatment of Metastatic Colorectal Cancer”, Keynote

Address, Asia Oncology Roundtable Forum Annual Meeting, Seoul, South Korea. Sept. 26, 2013 “Cancer Pharmacology I, II, and III”, MD Anderson Cancer Center - Medical

Oncology Board Review Course, Houston, TX. April 18, 2014 “An Overview of the UPCI Cancer Therapeutics and Phase I Research Program”,

Taipei Medical University Grand Rounds/Lecture Series, Taipei, Taiwan. April 20, 2014 “Treatment Strategies for Metastatic Colorectal Cancer – 2014 Update”, 11th

Annual Meeting of Asian Clinical Oncology Society Meeting, Taipei, Taiwan. April 20, 2014 “Development of New Agents for the Treatment of Metastatic Colorectal Cancer”,

11th Annual Meeting of Asian Clinical Oncology Society Meeting, Taipei, Taiwan. June 10, 2014 “Front-Line Treatment Approaches for Metastatic Colorectal Cancer - 2014”, Scott

Wadler Memorial Lectureship, Cornell Weill Cancer Center Grand Rounds, New York, NY.

July 27, 2014 “Principles of Clinical Pharmacology”, 2014 AACR-ASCO Vail Workshop in

Clinical Cancer Research, Vail, CO. Aug. 18, 2014 “Cancer Pharmacology I, II, and III”, George Washington University - Medical


Oncology Board Review Course, Houston, TX. Sept. 24, 2014 “The Role of Supportive Care in Cancer Therapy”, International Oncology

Symposium, Astana, Kazakhastan. Sept. 25, 2014 “Cancer Drug Development and Phase I Trials”, International Oncology

Symposium, Astana, Kazakhastan. Sept. 25, 2014 “An Update on the Treatment of Metastatic Colorectal Cancer”, International

Oncology Symposium, Astana, Kazakhastan. Oct. 17, 2014 “Cancer Drug Development and Early-Phase Clinical Trials at UPCI”, Beijing

University Cancer Hospital, Beijing, China. Oct. 18, 2014 “Targeted Therapy in the Treatment of Metastatic Colorectal Cancer – Present

and Future Directions”, Beijing International GI Oncology Summit, Beijing, China. Oct. 19, 2014 “Clinical Development of Chinese Herbal Medicine – PHY906 as a Paradigm”,

2014 International Oncology Forum of Traditional Chinese Medicine, Shanghai, China.

Oct. 20, 2014 “Treatment of Metastatic Colorectal Cancer”, Shanghai University of Traditional

Chinese Medicine, Shanghai, China. Dec. 17, 2014 “Treatment of Metastatic Colorectal Cancer in the Front-Line Setting – 2014 in

Review”, University of Pittsburgh Cancer Institute Grand Rounds, Pittsburgh, PA March 16, 2015 “Treatment of Wild-Type KRAS Metastatic Colorectal Cancer”, EGFR Oncology

Network Annual Meeting, Berlin, Germany

March 17, 2015 “Quality of Life in the Treatment of Metastatic Colorectal Cancer?”, EGFR Oncology Network Annual Meeting, Berlin, Germany

July 28, 2015 “Principles of Clinical Pharmacology”, 2015 AACR-ASCO Vail Workshop in



Oncology Board Review Course, Houston, TX. Sept. 25, 2015 “Treatment of Metastatic Colorectal Cancer in the Front-Line Setting – 2015 in

Review”, Alhambra Medical Center Grand Rounds, San Gabriel, CA. March 23, 2016 “Update on Treatment of Colorectal Cancer”, UPCI ASCO-GI Review 2016,

Pittsburgh, PA. May 25, 2016 “Clinical Development of Chinese Herbal Medicine – PHY906 as a Paradigm”,

State of the Science NCI CAM Workshop, Bethesda, MD. June 25, 2016 “Update on Treatment of Colorectal Cancer”, UPCI ASCO Review 2016 (Program

Chair), Pittsburgh, PA. July 28, 2016 “Principles of Clinical Pharmacology”, 2016 AACR-ASCO Vail Workshop in


Oncology Board Review Course, Washington, DC. Sept. 2, 2016 “Asan Cancer Institute Symposium 2016, Early-Phase Clinical Trials and

Personalized Medicine in Cancer Therapy”, Keynote Address, Asan Cancer Institute, Seoul, South Korea.

Sept. 21, 2016 “Cancer Pharmacology I, II, and III”, MD Anderson Cancer Center - Medical

Oncology Board Review Course, Houston, TX. Sept. 24, 2016 “Updates in Colorectal Cancer”, 5th Annual Advances & Controversies in Malignant

Hematology and Oncology, Chicago, IL. March 20, 2017 “An Overview of the UPCI Cancer Therapeutics and Phase I Research Program”,

National Cheung Kung Medical School. Tainan, Taiwan. March 22, 2017 “An Update on the Treatment of Metastatic Colorectal Cancer”, Taipei Medical

University and Taipei Cancer Center/Univ of Pittsburgh Cancer Institute Joint Symposium, Taipei, Taiwan.

March 30, 2017 “Chinese Herbal Medicine PHY906 as a Modulator of Chemotherapy in the

Treatment of Metastatic Colorectal Cancer: East Meets West”, National University of Athens Special Symposium, Honorary Medical Degree Ceremony, Athens, Greece.

April 9, 2017 “Personalized Medicine and Targeted Therapy in Cancer Treatment – 2017 Update”, AHMC Healthcare International Symposium of Cancer Precision Medicine, San Gabriel, CA.

June 5, 2017 “Evolution of Front-Line Treatment of Metastatic Colorectal Cancer”, Systemic

Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches (Session Chair), ASCO 2017 Annual Meeting, Chicago, IL.

June 24, 2017 “Update on Treatment of Colorectal Cancer”, UPCI ASCO Review 2017 (Program

Chair), Pittsburgh, PA. Aug. 1, 2017 “Precision Medicine Cancer Clinical Trials”, 2017 AACR-ASCO Vail Workshop in


Oncology Board Review Course, Alexandria VA. Sept. 13, 2017 “Cancer Pharmacology Review”, Cleveland Clinic Taussig Cancer Center,

Cleveland, OH. Sept. 14, 2017 “Cancer Pharmacology I, II, and III”, MD Anderson Cancer Center - Medical

Oncology Board Review Course, Houston, TX. Sept. 27, 2017 “Management of 5-Fluorouracil Treatment with Therapeutic Drug Monitoring

(TDM)”, 15th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology Meeting (IATDMCT), Kyoto, Japan.

Sept. 28, 2017 “Therapeutic Drug Monitoring of 5-Fluorouracil: An Approach Whose Time Has

Come”, 15th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology Meeting (IATDMCT), Kyoto, Japan.

Sept. 29, 2017 “Precision Medicine with 5-FU Therapeutic Drug Monitoring”, Shizuoka Cancer

Center, Mishima, Japan. Oct. 4, 2017 “Chinese Herbal Medicines as Modulators of Chemotherapy in the Treatment of

Metastatic Colorectal Cancer”, Univ of Virginia Cancer Center Grand Rounds, Charlottesville, VA.

Oct. 12, 2017 “Thymidylate Synthase as a Therapeutic Target in the Treatment of Metastatic

Colorectal Cancer”, Vanderbilt-Ingram Cancer Center Seminar Series, Nashville, TN.

Nov. 9, 2017 “Precision Medicine Clinical Trials in the U.S.”, 4th Annual AACR New Horizons in

Cancer Research, Shanghai, China. Nov. 14, 2017 “Development of Biomarkers for PHY906 and Other Chinese Herbal Medicines in

the Treatment of Metastatic Colorectal Cancer”, Society of Integrative Oncology 14th International Conference, Chicago, IL.

April 14, 2018 “An Update on the Treatment of Metastatic Colorectal Cancer - 2018”, Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Molecular Targeted and Immunotherapy Approaches (Session Chair), 2018 Annual AACR Meeting, Chicago, IL.

April 15, 2018 “Precision Medicine Clinical Trials in the U.S.”, 2018 Annual AACR Meeting,

Chicago, IL. Aug. 1, 2018 “Precision Medicine Cancer Clinical Trial Designs: The Role of Umbaskets”, 2018

AACR-ASCO Vail Workshop in Clinical Cancer Research, Vail, CO. Aug. 13, 2018 “Cancer Pharmacology I, II, and III”, George Washington University - Medical

Oncology Board Review Course, Alexandria VA. Sept. 26, 2018 “Cancer Pharmacology I, II, and III”, MD Anderson Cancer Center - Medical

Oncology Board Review Course, Houston, TX. Sept. 28, 2018 “Thymidylate Synthase as a Translational Regulator and Mediator of Drug

Resistance in Colorectal Cancer”, Montefiore-Albert Einstein Cancer Center Seminar Series, New York, NY.

Jan. 9, 2019 “Development of Chinese Herbal Medicines as Modulators of Chemotherapy in the

Treatment of Metastatic Colorectal Cancer”, Univ of Florida Health Cancer Center Grand Rounds, Gainesville, FL.

April 23, 2019 “PHY906 as a Model for the Development of Chinese Herbal Medicine in the

Treatment of Metastatic Colorectal Cancer”, NCI-NSCF International Workshop, Beijing, China.

April 24, 2019 “Phase 2 Clinical Trial Designs for Chinese Herbal Medicine”, NCI-NSCF

International Workshop, Beijing, China. 3. OTHER RESEARCH-RELATED ACTIVITIES MEMBER, NIH/NCI STUDY SECTION COMMITTEES: 1995, 1996 Ad Hoc Reviewer: NIH/NCI Experimental Therapeutics I Study Section 1995, 1996 Ad Hoc Reviewer: NIH/NCI Experimental Therapeutics II Study Section 1996-2000 Full Member: NIH/NCI Experimental Therapeutics I Study Section 1997-2000 Chairman: NIH/NCI Experimental Therapeutics I Study Section 1999-2001 Chairman, NIH/NCI Special Emphasis Panel Experimental Therapeutics I/II Study

Section 2008 Ad Hoc Reviewer: NCI-CCSG Review, University of Miami Sylvester Cancer Center,

Feb. 2008 2008-2013 Full Member: NCI Subcommittee A – NCI Cancer Centers 2010-present NCI Investigational Drug Steering Committee 2011-2013 Chairman: NCI Subcommittee A – NCI Cancer Centers 2012-present NCI Experimental Therapeutics (NeXT) Committee 2016 Ad Hoc Reviewer: NCI-CCSG Review, Moffitt Cancer Center, May 2016 2016-present Full Member: NCI Subcommittee F

MEMBER, NATIONAL/INTERNATIONAL COMMITTEES: 1996-1998 AACR Research Fellowships Committee 1997-1998 AACR Special Memberships Committee 1997-2004 New England Cancer Society Executive Committee 1998 AACR Special Memberships Committee, (Chairman) 1998-2004 Scientific Review Committee for the National Health Research Institutes (NHRI) of Taiwan 2000-2002 AACR Scientific Program Committee 2003-present Global Consortium for Chinese Herbal Medicine, Clinical Research Committee

(Chair) 2005-2007 ASCO Scientific Program Committee 2006-2007 ASCO Scientific Program Committee (Track Leader, Developmental Therapeutics) 2005-2007 ASCO Grant Selection Committee 2009-2015 Presidential Science Prize of Taiwan, Life Sciences Selection Committee 2011-2014 AACR Scientific Program Committee 2012-2015 ASCO Scientific Program Committee 2012-present AACR Exhibits Committee 2013-present AACR Basic Cancer Research Fellowships Scientific Review Committee 2014-2015 ASCO Scientific Program Committee (Track Leader, Colorectal Cancer) 2014-2016 AACR Clinical Research and Experimental Therapeutics Awards Committee 2014-present AACR Colon Cancer Research Fellowships Scientific Review Committee 2015-present International Association of Therapeutic Drug Monitoring and Clinical Toxicology

(IATDMCT) Oncology Scientific Committee 2015-present Global Consortium for Chinese Herbal Medicine, Executive Council 2016-2018 AACR NextGen Grants for Transformative Cancer Research 2017-present AACR Educational Committee and AACR Scientific Program Committee 2019-present AACR Exhibits Committee (Chair) MEMBER/REVIEWER, INTERNATIONAL GRANT REVIEW COMMITTEES: 2005-present National Health Research Council of Italy 2005-present University of Hong Kong, University Grants Committee 2008-present Singapore National Medical Research Council Grants Committee 2013 Taiwan NHRI Cancer Center Review Committee MEMBER, NCI CANCER CENTERS SCIENTIFIC ADVISORY BOARDS: 2006-present Albert Einstein Cancer Center 2007-present Dartmouth-Hitchcock Norris-Cotton Cancer Center 2012-present Herbert Irving-Columbia Cancer Center (Chair: 2015-2018) 2012-present USC Norris Cancer Center 2012-present Univ. of Vermont Cancer Center (Chair: 2012-2018) 2013-present Case Western Seidman Cancer Center 2013-present Medical University of South Carolina Hollings Cancer Center 2014-present Indiana University Simon Cancer Center 2016-present University of Arizona Cancer Center (Chair: 2016-present) 2017-present Karmanos Cancer Institute 2017-present University of Michigan Cancer Center 2017-present Duke Cancer Institute 2018-present University of Kentucky Markey Cancer Center 2019-present St. Jude’s Cancer Center

REVIEWER/CONSULTANT, NCI CANCER CENTERS 2014 Univ of Wisconsin Cancer Center 2015 UNC-Lineberger Cancer Center 2016 Univ of Arizona Cancer Center 2016 Univ of Kentucky Markey Cancer Center 2016 Thomas Jefferson Kimmel Cancer Center 2016 Univ of Michigan Cancer Center 2017 Yale Cancer Center 2018 St. Jude’s Cancer Center MEMBER, INTERNATIONAL CANCER CENTERS SCIENTIFIC ADVISORY BOARDS: 1998-present Scientific Advisory Board for Taiwan Cooperative Oncology Group, National Health Research Institutes of Taiwan 1999-present Scientific Advisory Board, Division of Cancer Research, NHRI, Taiwan 2005-2010 Chair, Scientific Advisory Board, National Institute of Cancer Research, Taiwan MEMBER, SCIENTIFIC ADVISORY BOARDS: 2000-2005 Adventrx Pharmaceuticals, San Diego, CA 2005-present Celator, Vancouver, British Columbia 2010-present Saladex, Bethlehem, PA 2011-present Salzburg Therapeutics, Winston-Salem, NC 2017-present Hope Biosciences, Irvine, CA MEMBER, PHILANTHROPIC FOUNDATIONS: 2012-2016 Chris4Life Foundation, Washington, D.C. 2016-present Colon Cancer Alliance, Washington, D.C. MEMBER, EDITORIAL BOARDS: 1996-2005 Biochemical Pharmacology 1997-present International Journal of Oncology 1997-1999 Colon Cancer: The Cutting Edge (Editor) 2000-present Clinical Colorectal Cancer (Founding Editor-in-Chief) 1999-2005 Cancer Research 2000-2006 Clinical Cancer Research 2003-present Oncology Special Edition 2004-present Current Reviews in Hematology and Oncology 2004-present Journal of Chemotherapy 2006-present Oncology 2006-present Oncology News International 2006-present Principles and Practice of Oncology: The Cancer Journal 2008-present Clinical Oncology News 2008-present Journal of Clinical Oncology 2008-present Oncology Research (Co-Editor-in-Chief) 2009-present Journal of Experimental and Clinical Medicine JOURNAL REFEREE: Reviewer for: Cancer Research, Clinical Cancer Research, Journal of Clinical Oncology, Annals of Oncology, Journal of the National Cancer Institute, Cancer, New England Journal of Medicine, Nature Oncology, Oncogene, Journal of Biological Chemistry, Journal of Clinical Investigation, Molecular and Cellular Biology, Lancet Oncology, Proceeding National Academy of Science, Nucleic Acids Research, RNA, Molecular

Pharmacology, Molecular Cancer Therapeutics, Cancer Chemotherapy Pharmacology LIST of CURRENT RESEARCH INTERESTS:

1. Investigate the molecular elements that regulate the expression of thymidylate synthase. 2. Investigate the role of siRNAs as therapeutic agents for cancer chemotherapy. 3. Investigate the molecular mechanisms of resistance in human colon cancer stem cells. 4. Investigate the role of Chinese herbal medicine as a modulator for cancer chemotherapy in the

treatment of colorectal cancer and other GI cancers. 5. Pre-clinical development of small molecules and Chinese herbal medicines in the treatment of

colorectal cancer. 6. Early-phase clinical development of novel agents and combination regimens for the treatment of human

cancers. SERVICE: 1. University and Medical School MEMBER, UNIV OF PITTSBURGH CANCER INSTITUTE/HILLMAN CANCER CENTER COMMITTEES: 2010-present Co-Leader, UPCI Cancer Therapeutics Program 2010-present UPCI Clinical Executive Committee 2010-present UPCI Senior Leadership Committee 2010-present UPCI Clinical Research Oversight Committee 2010-present UPCI Biomarkers Steering Committee 2010-2013 Chair, UPCI Clinical Pharmacology Analytical Facility Advisory Committee 2011-present Division of Hematology-Oncology Fellowship Curriculum Committee 2011-present Oncology EMR Governance Committee 2013-present UPCI Chemical Biology Facility Committee 2016-present UPCI/HCC Shared Resources Oversight Committee 2019-present HCC Pharmacy and Therapeutics Committee MEMBER, UPMC COMMITTEES: 2014-present UPMC Oncology Executive Management Committee MEMBER, UNIV OF PITTSBURGH COMMITTEES: 2011-present Material Transfer Agreement Exception Committee MEMBER, YALE CANCER CENTER/YALE SCHOOL OF MEDICINE COMMITTEES: 1996-2010 Co-Director, Developmental Therapeutics Program, Yale Cancer Center 1996-2010 Yale Cancer Center Executive Committee 1996-2010 Yale Cancer Center Membership Committee 1996-2001 Yale Cancer Center Protocol Review Committee 2001-2005 Yale School of Medicine Tenure Allotment Committee 1996-2005 VACT Cancer Committee (Chair) 2002-2004 VHA PET Center Advisory Group 2004-2009 Yale Cancer Center Appointment and Promotions Committee 2004-2010 Yale Cancer Center Scientific Committee 2006-2010 Yale Cancer Center Clinical Research Steering Committee (Chair) 2006-2010 Yale Cancer Center Senior Leadership Committee 2006-2010 Yale School of Medicine PET Center Advisory Board

MEMBER, YALE DEPT OF MEDICINE COMMITTEES: 1998-2005 Appointment and Promotions Committee, Dept. of Internal Medicine, Yale School of

Medicine 1998-2005 Appointment and Promotions Senior Committee, Yale School of Medicine 1998-2010 Intern Selection Committee, Dept. of Internal Medicine, Yale School of Medicine 2004-2009 Joint Appointment and Promotions Committee, Dept of Internal Medicine and Yale

Cancer Center, Yale School of Medicine MEMBER, YALE CANCER CENTER/YALE-NEW HAVEN HOSPITAL (YNHH) COMMITTEES: 2004-2010 YNHH Cancer Committee 2006-2008 YNHH-Medical Oncology Long Wharf Transition Committee (Co-Chair) 2006-2010 YNHH Oncology Pharmacy and Therapeutics Committee (Chair) 2006-2010 YNHH/YCC Campaign Fundraising Committee 2008-2010 Yale Cancer Center/Yale Smilow Cancer Hospital Operations Steering Committee 2. Community activities MEMBER, HOSPITAL MEDICAL STAFF: NIH Clinical Center and Bethesda Naval Hospital – 1986-1996 VACT Healthcare System, West Haven, CT – 1996-2006 Yale-New Haven Hospital, New Haven, CT – 1996-2010 UPMC Presbyterian/Shadyside, Pittsburgh, PA – 2010-present HOST OF YALE CANCER CENTER ANSWERS: Founding host (2006-2010) of a weekly radio program on WNPR – CT Public Radio that serves as an important community outreach effort of the Yale Cancer Center. Each show highlights a cancer-related topic. To date, over 220 original 30-minute programs have been produced and archived online in audio and written format. This show is downloaded from the YCC website over 15,000 times per month and has been ranked first for cancer center podcasts and ranked second overall for cancer podcasts on iTunes.

Documents

BIOGRAPHICAL Name: Edward Chu, MD Birth Date: Home … · BIOGRAPHICAL . Name: Edward Chu, MD Birth Date: December 19, 1958 Home Address: 121½ Springhouse Lane Birth Place: Detroit,